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SYNTHESIS AND CHARACTERIZATION OF POTENTIAL DRUG DELIVERY 
SYSTEMS USING NONIONIC SURFACTANT “NIOSOME” 
 
Sukit Leekumjorn 
ABSTRACT 
 
Niosomes are synthetic microscopic vesicles consisting of an aqueous core 
enclosed in a bilayer consisting of cholesterol and one or more nonionic surfactants.  
They are made of biocompatible, biodegradable, non-toxic, non-immunogenic and non-
carcinogenic agents which form closed spherical structures (self assembly vesicles) upon 
hydration.  With high resistance to hydrolytic degradation, niosomes are capable of 
entrapping many kinds of soluble drugs while exhibiting greater vesicle stability and 
longer shelf life. 
In this work, a potential drug delivery system has been designed, synthesized and 
characterized.  For the synthesis of niosomes, a hydration process was developed with 
varying design parameters such as mass per batch, angle of evaporation, rotation speed of 
vacuum rotary evaporator and nitrogen flowrate to produce uniform thin film in 50 ml 
round bottom flask.  The rehydration process was developed by varying the choice of 
solvents (H2O, phosphate buffer solution (PBS) and PBS/5(6)-carboxyfluorescein (CF) as 
a drug model) and hydrating temperature of below and above gel transition temperature.  
Lastly, a sonication process to produce unilamellar vesicles was partially optimized based 
on the particle distribution and the number of vesicles formed with sonication time. 
As a result of this process, unilamellar and multilamellar vesicles were formed 
with the combination of different nonionic surfactants (sorbitan monostearate-Span 60, 
sorbitan monopalmitate-Span40 and sorbitan monolaurate-Span20), cholesterol and an 
electrostatic stabilizer (dicetyl phosphate).  The vesicles were examined using light 
scattering optical microscopy and UV microscopy.  Optical sensing technology (Particle 
Sizing System) is used to determine the vesicles’ size distribution.  Gel exclusion 
chromatography (GEC) is discussed as a method to separate unencapsulated CF while 
retaining vesicle integrity.  Particle Sizing System and luminescence spectrophotometer 
were used to determine CF encapsulation percentage and leakage. 
Result: Span 20, Span 40 and Span 60/Niosomes were made with mean particle 
size of 0.95-0.99 µm.  Typical concentrations of vesicle per ml/per mass of surfactant 
used were in the range of . Typical encapsulation efficiencies were in the 
range of 48.8-62.9% for all three Span/Niosome systems.  Niosomes were found to be 
stable for 9 days.  The largest vesicles were observed with Span 60 with highest 
entrapment efficiency as compared to Span 20 and Span 40. 
81079.146.1 ×−
 
 x
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CHAPTER ONE:  INTRODUCTION 
 
 Development of new drugs is difficult, expensive and rather time consuming in 
the process involving preclinical testing, investigational new drug application (IND), 
clinical trials, phase I, II, & III, new drug application (NDA) and FDA approval.  
Improving safety and efficacy of existing drugs has been attempted using different 
methods such as individualizing drug therapy, dose titration and therapeutic drug 
monitoring and, most importantly, delivering drugs at controlled rates at targeted sites [ ]1 .  
Drug delivery systems could provide extended circulating half-lives so that less drug is 
required for therapeutic effectiveness (for a longer period of time) relieving the patient of 
side effects caused by non-specific tissue uptake and provide protection against 
enzymatic degradation [ ]2 .  Recently discovered biological drugs often require drug 
delivery systems due to several side effects of the active ingredients to minimize the 
number of injections required during the course of therapy. 
 Today, lipid and nonionic surfactant based drug delivery systems have drawn 
much attention from researchers as potential carriers of various bioactive molecules that 
could be used for therapeutic applications.  Several commercial liposome/niosome-based 
drugs have already been marketed with a great success.  For example, liposomes and 
niosomes have been used to encapsulate colchicines [ ]3 , estradiol [ ]4 , tretinoin [ , ]5 6 , 
dithranol [ , ]7 8 , enoxacin [ ]9  for applications such as anticancer, anti-tubercular, anti-
leishmanial, anti-inflammatory, hormonal drugs and oral vaccines [ , , , , , , , ]10 11 12 13 14 15 16 17 . 
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Based on these successes and the advantages of niosomes over liposomes, the 
objective of this research was to determine an appropriate synthesis technique for a 
niosome drug carrier system, to characterize the resultant particles and to encapsulate 
5(6)-carboxyfluorescein (CF) to demonstrate encapsulation efficiency, and 
leakage/release over time. 
 
 
 
 
 
CHAPTER TWO:  LITERATURE REVIEW 
 
The focus of this literature review is on liposomes and niosomes as drug delivery 
systems (synthesis technique, targeting surface modification, biocompatibility and their 
delivery applications). 
 
2.1 Liposomes 
A liposome is a microscopic vesicle consisting of an aqueous core enclosed in one 
or more phospholipid layers, used to convey vaccines, drugs, enzymes, or other 
substances to target cells or organs [ ]18 .  Liposomes are bilayered structures made of 
amphipathic (both hydrophobic and hydrophilic) phospholipids/cholesterol that 
spontaneously form closed structures when hydrated in aqueous solutions (Figure 1, 
Figure 2 and Figure 3). 
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Hydrophilic head group Hydrophobic tails 
Sigma-Aldrich Catalog
Figure 1: Chemical structure of Phosphatidyl-choline (PC) 
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Figure 2: Possible formation of liposome vesicles when hydrating in aqueous solution 
www.avantilipids.com
www.avantilipids.com 
 
 
0.05 mm
 
Figure 3: PC immerse in water to form bilayer.  Elongation and several vesicles were observed 
 
In Figure 2, depending on the number of bilayers, liposomes are classified as 
multilamellar (MLV), large unilamellar (LUVs) or small unilamellar (SUVs) and range in 
size from 0.025~20 µm in diameter.  The size and morphology of liposomes are regulated 
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by the method of preparation and composition.  Mainly, factors that contribute to the 
overall vesicle formation are phase transition temperature, stability and cholesterol. 
 
2.1.1 Phase Transition Temperature of Lipids 
The phase transition temperature is defined as the temperature required to induce 
a change in the lipid physical state from the ordered gel phase (hydrocarbon chains are 
fully extended and closely packed) to the disordered liquid crystalline phase 
(hydrocarbon chains are randomly oriented and fluid) [ ]19 . There are several factors which 
directly affect the phase transition temperature; however, the length of the hydrocarbon 
chain provides a major contribution to the overall transition temperature (Table 1, Figure 
4).  It is noted that PC=phosphatidylcholine, PE=phosphatidylethanolamine, 
PS=Phosphatidylserine, PA=phosphatidic acid and PG=phosphatidyglycerol. 
 
Table 1: The effect of transition temperature vs. acyl composition (hydrocarbon chain length) 
Phase Transition Temperature (C) Acyl Composition 
avantilipids.com PC PE PS PA PG 
12 -1 29 17 31 -3 
13 14 - - - - 
14 23 50 35 50 23 
15 33 - - - - 
16 41 63 54 67 41 
17 48 - - - - 
18 55 74 68 75 55 
19 60 - - - - 
20 66 83 - - - 
21 72 - - - - 
22 75 - - - - 
23 79 - - - - 
24 80 - - - - 
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 www.avantilipids.com
Figure 4: The effect of transition temperature vs. acyl composition 
 
As the hydrocarbon chain length increases, molecular (van der Waals) interactions 
become stronger, requiring more energy to disrupt the ordered packing; thus the phase 
transition temperature increases (Figure 4).  The stability of the final structure depends on 
the type of emulsion which is created (oil in water or water in oil).  The larger the 
hydrophobic chains, the greater the intermolecular force on the hydrophilic part of the 
molecule.  This forms a structure which extends the hydrophilic end (head) into the water 
substrate while the hydrophobic chains (tails) are separated from this substrate by the 
 6
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intrabilayer spaces of the sphere.  In general, high transition lipids provide a stable (non-
leaky) delivery system [ ]20 . 
 
2.1.2 Stability/Surface Modification 
Lipid compounds that are easily oxidized (unsaturated) tend to have a shorter 
shelf life.  Stability issues due to hydrolytic degradation are a general problem with lipid 
products.  Aqueous formulations of drug products tend to be less stable since the 
presence of excess or bulk water leads to rapid hydrolytic degradation in lipid 
preparations [ , , ]21 22 23 .  This hydrolysis is dependant on several factors including pH [21], 
temperature [21, 23], buffer species [23], ionic strength, acyl chain length and headgroup [22], 
and the state of aggregation [22].  Nevertheless, there have been successes in delivering 
various drugs and therapeutic genes in both animal and human trials [ , , , , , , ]24 25 26 27 28 29 30 . 
In light of the short half-life of conventional liposomes, several researchers have 
introduced a protective coat by designing liposomes that are non-reactive or 
polymorphous [ , , ]31 32 33 .  Phospholipids with a polyethylene glycol (PEG) coating help 
prevent liposomes from sticking to each other and to blood cells or vascular walls [ ]34 .  
This coating also reduces the uptake of liposomal vesicles in the liver and extends 
circulation time [31].  Furthermore, by incorporating targeting ligands on the surface of the 
liposomes, it was possible to direct these vesicles to certain organs using the PEGlycation 
technique [ , , , ]35 36 37 38 .  Branched amino acids have also been incorporated on the surface 
of liposomal vesicles in order to stabilize the vesicle and to deliver to targeted sites [39, 40]. 
Today, liposomes are used in drug delivery systems [ , , ]41 42 43 .  For example, 
liposomal systems integrated with receptor protein conjugates are being studied for 
cardiovascular treatments targeting activated platelets [ ]44 .  Acoustic liposomes have been 
created for echocardiographic enhancement of pathological components of 
atherosclerotic lesions [44].  Modified liposome has been shown to attach to early 
atheroma in animal model when targeted to vascular cell adhesion molecule type 1 
(VCAM-1), or intercellular adhesion molecule-1 (ICAM-1) on atherosclerotic lesion [44, 
, ]45 46 .   
Furthermore, covalently bonded monoclonal antibodies to small unilamellar 
liposomes has been accomplished using dipalmitoyl lecithin and cholesterol and variable 
quantities of phosphatidylethanolamine substituted with the heterobifunctional cross-
linking reagent N-hydroxysuccinimidyl 3-(2-pyridyldithio) propionate (SPDP) [ ]47 .  
Figure 5 represents the molecular structure of heterobifunctional cross-linking reagent 
and modified liposome. 
 
A) N-hydroxysuccinimidyl 3-(2-pyridyldithio) propionate 
 
 
B) Dipalmitoylphosphatidylethanolamine 3-(2-pyridyldithiopropionate) 
Figure 5: Modified liposomes using phosphatidylethanolamine substitution 
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Once the modified liposomes were formed, they were then reacted and incubated with 
antibody derivatized with the same reagent at 5 to 20 fold molar excess and it was found 
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that more than 40% of antibody could be reproducibly bound to liposomes without the 
loss of encapsulated carboxyfluorescein [47].  By knowing the fact that several types of 
antibodies covalently bind to modify liposomes and the availability of anti-ICAM-1 and 
anti-VCAM-1, exploring the usage of these antibodies may improve drug delivery 
systems specifically targeting atherosclerotic plaque. 
 
2.1.3 Cholesterol 
Cholesterol (C27H45OH) is a cell membrane constituent found in most animal 
systems.  It modulates membrane fluidity, elasticity, and permeability by closing the gaps 
created by imperfect packing of other lipid species when proteins are embedded in the 
membrane [ ]48 .  Furthermore, cholesterol enables the formation of vesicles, reduces 
aggregation and provides greater stability [ ]49 .  Based on the size and orientation of 
cholesterol molecule during vesicle formation, the best molar ratio of lipid to cholesterol 
was reported to be one to one [ ]50 . 
 
2.1.4 Liposome Preparation & Mechanisms Associated with Drug Encapsulation 
There are two major techniques for making liposomes: dehydration-rehydration 
and reverse phase synthesis.  In this work, the dehydration-rehydration method was used 
(see Figure 6). 
 
 www.avantilipids.com
Figure 6: Preparation of liposome using dehydration/rehydration technique 
After the thin film is prepared, the aqueous phase is introduced.  Upon agitation, 
liposomes form multilamellar (MLV), large unilamellar vesicles (LUVs) or small 
unilamellar (SUVs) upon rehydration (Section 2.1).  While in the assembly mode, there 
are two primary mechanisms such as encapsulation (formation of liposomes passively 
entrapped water soluble drug in the interlamellar spaces) and partitioning (formation of 
liposomes passively entrapped organic soluble drug in the intrabilayer spaces). 
 
2.2 Niosomes 
 Because of a liposome’s instability, alternative nonionic surfactants have been 
investigated [20].  Using similar techniques, nonionic surfactant vesicles or “niosomes” 
have been synthesized [50].  These formulations use alternative materials to phospholipids 
such as Span 60, Span 40 and Span 20 (Table 1), which are inexpensive and widely 
available permitted food additives [50, 51, , , , , ]52 53 54 55 56 .  For example, niosomes has been 
used to encapsulate colchicines [3], estradiol [4], tretinoin [5,6], dithranol [7,8], enoxacin [9] 
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and for application such as anticancer, anti-tubercular, anti-leishmanial, anti-
inflammatory, hormonal drugs and oral vaccine [10, 11, 12, 13, 14, 15, 16, 17]. 
 
2.2.1 General Characteristics of Nonionic Surfactant 
 The ability of nonionic surfactant to form bilayer vesicles instead of micelles is 
dependant on the hydrophilic-lipophilic balance values (HLB) of the surfactant, the 
chemical structure of the components and the critical packing parameter [ ]57 .  The 
relationship between the structure of the surfactant including size of hydrophilic head 
group, and length of lipophilic alkyl chain in the ability to form vesicles is described in 
Figure 7. 
 
 
Figure 7: Critical packing parameter of surfactants [57]
 
The general form of a single bilayer vesicle is shown in Figure 8. 
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Figure 8: Bilayer membrane structure 
 12
Nonionic surfactants investigated in this research are shown in Table 2.  For HLB values 
greater than 6, cholesterol must be added to the surfactant in order for a bilayer vesicle to 
form [52].  For lower HLB values, cholesterol is added to make vesicles more stable as 
described earlier in Section 2.1.3.  Also, the addition of cholesterol enables more 
hydrophobic surfactants to form vesicles, suppresses the tendency of the surfactants to 
form aggregates, and lends greater stability to the bilayer membranes by raising the gel 
liquid transition temperature of the vesicle [53].  Below are the phase transition 
temperatures of nonionic surfactants (Table 3). 
 
Table 2: Chemical specifications of Sp20, Sp40, Sp60, cholesterol, dicetyl phosphate and CF 
Chemical Specification Description MW (g/mol) MW Formula HLB[54]
Sorbitan monolaurate 
(Span20) Clear viscous liquid  346.5 C18H34O6 8.6 
Sorbitan monopalmitate 
(Span40) Yellowish powder 402.6 C22H42O6 6.7 
Sorbitan monostearate 
(Span60) White powder 430.6 C24H46O6 4.7 
Cholesterol White powder 386.7 C27H46O N/A 
Dicetyl phosphate White powder 546.9 C32H67O4P N/A 
5(6)-carboxyfluorescein Yellowish powder 376.0 C21H12O7 N/A 
 
Table 3: Phase transition temperature of Sp20, Sp40, and Sp60 
Nonionic Surfactant Acyl composition Gel Transition Temperature 
Sorbitan monolaurate (Span20) C9 Liquid at room temperature 
Sorbitan monopalmitate (Span40) C13 46-47°C 
Sorbitan monostearate (Span60) C15 56-58°C 
 
The transition temperatures of surfactants increased 46-47°C to 56-58°C as the 
hydrocarbon length is increased (C9-C15).  This stability decreases leakage of the 
vesicles and stabilizes against osmotic gradients [53]. 
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2.3 Summary 
 Above all, liposomes and niosomes have been successfully used to entrap several 
types of water soluble drugs.  Niosome systems have been shown to be more chemically 
stable, commercially less expensive, and less cumbersome in handling, production and 
storage than liposomes [50]. 
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CHAPTER THREE:  DESIGN CONCEPT 
 
As a first step, optimization of the process design parameters for making 
niosomes was prepared.  This included parameters such as mass per batch, angle of 
evaporation, dehydration nitrogen flowrate, hydrating solvents, hydrating temperature 
and sonication time. 
 
3.1 Material and Equipment Selection 
All materials and equipments used in the experiments are listed below (Table 4 and Table 
5). 
Table 4: List of material used in the experiment 
Sigma Aldrich Cooperation 
Sorbitan Monostearate, Span 60 (S-7010) 
Sorbitan Monopalmitate, Span 40 (S-6885) 
Sorbitan Monolaurate, Span 20 (S-6635) 
Cholesterol; 5-cholesten-3β-ol (C-8503) 
Dicetyl Phosphate, Dihexadecyl phosphate (D-2631) 
Phosphate Buffered Saline, pH 7.4 (P-3813) 
Sodium Hydroxide (S-0899) 
Sephadex G-50 (G-50-80) 
Fisher Scientific 
Chloroform, 99%A.C.S. HPLC grade (C606-1) 
Triton X-100 (BP151) 
Biotium, Inc.  Hayward, California 
5-(and-6)-Carboxyfluorescein, catalog #51013 
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Table 5: List of equipment used in the experiment 
Mass balance: Denver Instrument Company A-250 
Buchi-Vaccum Controller V-800 
Buchi-Rotavapor R-200 
Buchi-Heating Bath B-490 
Rotary evaporator:  
Buchi Vac V-500 
Laboratory Supplies CO., INC 
Model G1125PIG 
115 Volts, 50-60 Hz, 3.5 Amps. Sonicator:  
Output 80 KC, 80 Watts 
Particle Sizing Systems (PSS), Model 770A 
AccusizerTM
AutodiluterPatParticle sizing:  
Partial Particle SizerTM
Fluorescence Spectrometer: Perkin Elmer, LS-3B 
Cooling System: PolyScience Refrigeration Circulation Model 90 
Olympus BH-2, 
4x, 10x, 20x Dplan 
40x Splan 
NFK 1.67 x LD125 
Microscope: 
NFK 6.7 x LD125 
Lecia Type 090-135.002 II/02 UV Microscope: LEP-LTD ARC Lamp 50W, HBO-AC, 6V max, 35W 
Sony CCD Color Video Camera Video Camera: Model SSC-C370 
Glassware:  50 ml Pyrex Mexico, 24/40 neck size, No. 4320A 
1-10 µL 
10-100 µL 
100-1000 µL Eppendorf Research Pipette:  
1000-5000 µL 
Container Wrap: PARAFILMR “M” Laboratory film 
Gel Exclusion Column: EconoPac 10DG column, Biorad Laboratories, Inc 
Water Filter System: Waterwise Model A30D/W3616 
 
Figure 9 shows the chemical structure of sorbitan monostearate (Span 60), 
sorbitan monopalmitate (Span 40) and sorbitan monolaurate (Span 20).  Their physical 
properties were reported in Table 2. 
 
 
 Sigma-Aldrich Catalog 
Figure 9: Chemical structure of Sp60 (A), Sp40 (B) and Sp20 (C) 
 
Span 20, Span 40 and Span 60 are widely available food additives and the main 
ingredient in some cosmetic applications.  They are characterized as amphipathic 
(hydrophobic head and hydrophilic tail) molecules that can spontaneously form closed 
structures when hydrated in aqueous solutions.  Dicetyl phosphate is also used in to 
prevent aggregation between vesicles and provide greater stability.  Chemical structure of 
dicetyl phosphate is shown in Figure 10. 
 
 Sigma-Aldrich Catalog 
Figure 10: Chemical structure of dicetyl phosphate 
 
Cholesterol, 5-cholesten-3β-ol (Figure 11) is used in combination with nonionic 
surfactant. 
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 Sigma-Aldrich Catalog 
Figure 11: Chemical structure of cholesterol 
 
The structure of the resultant niosome is shown in Figure 12. 
 
 
 
 17
a) 2-dimension 
 
b) 3-dimension
andrew.cmu.edu/~jamesv/ Research-Lab.html 
Figure 12: Proposed structure of niosome vesicle (a) in 2D (A=span, B=cholesterol, C=dicetyl 
phosphate), in 3D (b) 
 
3.2 Encapsulation Technique 
Dehydration/rehydration technique is used to form niosomes.  During rehydration, 
solution containing 5(6)-carboxyfluorescein (Figure 13), as a drug model, in sodium 
hydroxide (NaOH) and phosphate buffered saline (PBS) is used. 
 
 Biotium Catalog 
Figure 13: Chemical structure of 5(6)-carboxyfluorescein 
 
Premade CF solutions, in the range of 5 mM, exhibit self-quenching (higher 
concentration of CF molecules with a bright fluorescein color decrease the intensity 
reading of the fluorescent from fluorometer) and can be entrapped inside niosomes, 
exhibiting low intensity fluorescence.  Brightness vs. number of molecules of several 
types of dyes is shown in Figure 14 where self-quenching occur at higher concentration. 
 
 Amersham Biosciences 
Figure 14: Brightness vs. quenching, self quenching properties of common fluorescent agents 
 
However, when niosomes are broken down with Triton X-100 (nonionic detergent used 
to solubilize membranes), the changes in the intensity can be used to estimate the amount 
of CF entrapped inside the niosomes. 
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3.3 Separation Technique 
Excess CF remaining in the hydrating solution was separated from the vesicles by 
gel exclusion chromatography (GEC).  The gel matrix consists of spherical beads with 
pores of a specific size distribution.  As small molecules diffuse into the gel pores, their 
flow through the column is retarded, while large molecules bypass the pores and are 
rapidly eluted.  Sephadex G-50 was used as a packing material in the column (Table 6), 
to separate niosomes from other molecules such as unencapsulated CF, cholesterol 
molecules, small micelles, and fragments of surfactants (Figure 15). 
 
Table 6: Gel exclusion packing materials and their specifications 
Gel Type 
(Sigma) 
Fractionation Range, 
Globular Proteins 
(Da) 
Approx. Bed Volume 
(ml swelled per gram 
dry 
Approx. Dry 
Bead Diameter 
(µm) 
Approx. Void 
Volume (% of total 
bed volume) 
G-10 ≤700 2–3 40-120 10-30 
G-15 ≤1500 2.5–3.5 40-120 10-30 
G-25 1000–5000 4–6 50–150 20-40 
G-50 1500–30000 9–11 50–150 20-40 
 
 
Figure 15: Schematic drawing of gel exclusion chromatography (GEC) separation 
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Resolution of separation depends on particle size, pore size, flow rate, column 
dimensions, and sample volume.  In general, the highest resolution is obtained with low 
flow rates, long/narrow columns (25-50 ml column volume, Figure 16), small-particle-
size gels (Sephadex G50), small sample volumes and large differences in molecular 
weights (molecular weight of CF as compare to niosomes). 
 
EconoPac 10DG column 
Bed volume 20 ml 
Total column volume 30 ml 
Packing buffer PBS 
Flow rate 1.1-1.5 ml/min 
Column material Polypropylene 
Frit material Polypropylene 
Desalting gel Porous bead 
pH 2-10 pH range 
Operating temperature 2-45 °C 
 
www.bio-rad.com 
Figure 16: Econo-Pace 10DG column specification 
 
Table 7: Recommended volume of sample per column volume 
Column Volume (www.bio-rad.com) Volume of Sample 
100-200 ml 0.5 ml 
50-100 ml 0.25 ml 
25-50 ml 0.125 ml 
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3.4 Particle Characterization 
Particle characterization is accomplished using light scattering optical 
microscopy, UV microscopy, luminescence spectroscopy (fluorometry) and light 
scattering and light obscuration techniques.  Both UV and light scattering optical 
microscope provide a magnification range from ×−× 4004  plus  eye piece 
magnification.  The light microscope also gives an estimation of particle diameter using a 
hemocytometer (Figure 17).  The UV microscope provides a dark background image with 
a trace of fluorescence entrapped inside the niosome. 
×10
 
 
0.05 mm
Figure 17: Hemocytometer specification: square sized (0.05 mm) 
 
As described earlier, the excitation and emission wavelength of CF are Iexcitation 
and Iemission are 492/514 nm respectively.  This property can be used in fluorometry to 
detect CF, and the intensity of the signal is proportional to intensity reading over diluted 
ranges.  By measuring the intensity of fluorescence and calibrating against sets of 
standard solutions, fluorometer can be use to detect CF in extremely dilute solutions. 
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Particle sizing of the vesicle dispersion can be achieved by the Particle Sizing 
System 780 (PSS).  This technology utilizes forward light scattering and light obscuration 
technique equipped with auto-dilution scheme (Figure 18). 
 
 
Particle Sizing System 
Figure 18: PSS auto-diluter scheme 
 
Scattered light is collected onto a photodiode to produce an electrical pulse, the 
voltage which is proportional to the light intensity detected from each particle and for 
each particle size.  The photodiode pulses are amplified and this electrical signal 
measured by a counter.  In general, PSS-780 has the ability to count and size particles in 
the range of 0.5-500 µm. 
The operation of the particle sizer and counter depends, primarily, on the low 
concentration value of the particles in solution.  Autodilution in the PSS-780 reduces 
concentration to eliminate the possibility that multiple particles pass through the 
detecting chamber.  Higher concentration solutions exhibit higher probabilities of false 
readings because more than one particle might pass between the photodiode array 
detector and the light scattering emitter.  By requiring very low concentrations the 
possibility of light extinction due to the passage of more than one particle is reduced. 
 22
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CHAPTER FOUR:  PROCEDURES AND EXPERIMENT PROTOCOLS 
 
4.1 Procedures 
The basic procedures listed below were determined based on literature surveys.  
Design parameters were then varied to optimize the procedure (Section 4.2) 
 
4.1.1 Buffer Solution Preparation 
1) For 10x solution, open one phosphate buffered saline package (Sigma, P-
3813), place the powder into 1 L container and fill up the bottle with 100 ml 
of H2O (equivalent ultrapure water, Waterwise Model A30D/W3616). 
2) For 1x solution, open one phosphate buffered saline package (Sigma, P-3813), 
place the powder into 1 L container and fill up the bottle with 1.0 L of H2O. 
 
4.1.2 Niosome Stock Solution
1) For Span 60/cholesterol/DCP stock solution: weigh out 0.1600 g of dicetyl 
phosphate (Sigma, D-2631), 0.8800 g of cholesterol (Sigma, C-8503) and 
1.0000 g of Span 60 (Sigma, S-7010) in the mass balance and place it in into a 
clean, dry 50 ml or 100 ml screw type bottle.  These values were precalculated 
to have a molar ratio of 7.5/7.5/1 of Span60, cholesterol and DCP respectively 
[ , ]58 59 .  Pipette 100.0 ml chloroform into the bottle.  Close the bottle tightly 
and place it in a warm water bath, at 40°C, to ensure complete dissolution. 
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2) For Span 40/cholesterol/DCP stock solution: weigh out 0.1600 g of dicetyl 
phosphate (Sigma, D-2631), 0.8800 g of cholesterol (Sigma, C-8503) and 
0.9360 g of Span 60 (Sigma, S-6885) in the mass balance and place it in into a 
clean, dry 50 ml or 100 ml screw type bottle.  These values were precalculated 
to have a molar ratio of 7.5/7.5/1 of Span 40, cholesterol and DCP 
respectively [58, 59].  Pipette 100.0 ml chloroform (Fishersci, C606-1) into the 
bottle.  Close the bottle tightly and place it in a warm water bath, at 40°C, for 
10 minutes to ensure complete dissolution. 
3) For Span 20/cholesterol/DCP stock solution: weigh out 0.1600 g of dicetyl 
phosphate (Sigma, D-2631), 0.8800 g of cholesterol (Sigma, C-8503) and 
0.8060 g of Span 20 (Sigma, S-6635) in the mass balance and place it in into a 
clean, dry 50 ml or 100 ml screw type bottle.  These values were precalculated 
to have a molar ratio of 7.5/7.5/1 of Span 20, cholesterol and DCP 
respectively [58, 59].  Pipette 100.0 ml chloroform (Fishersci, C606-1) into the 
bottle.  Close the bottle tightly and place it in a warm water bath, at 40°C, for 
10 minutes to ensure complete dissolution. 
 
4.1.3 5(6)-Carboxyfluorescein (5 mM) in PBS Stock Solution 
1) Pipette 4.0 ml of H20 in to the 100 mg CF container (Biotium, 51013) and 
place the solution into a 60 ml plastic container (milky yellow should be 
observed). 
2) Pipette 11.0 ml of NaOH (0.05 M, pH≈13) into the container at 0.5 ml interval 
of injection (clear orange solution should be observed). 
 25
3) Pipette 32.9 ml H2O into the container (clear green-orange should be 
observed).  The value was precalculated to achieve 5 mM CF stock solution. 
4) Wrap the container with the aluminum foil and keep it in the refrigerator for 
further analysis. 
5) Calibration using fluorometer is required for the successive batch of CF stock 
solution to maintain the correct intensity readings. 
 
4.1.4 Gel Chromatography Column Preparation 
1) Weight out 5.0000 g of Sephadex G-50 (Sigma, G-50-80) in to a 500 ml 
beaker.  Fill up the beaker with PBS to twice the original volume of Sephadex 
G-50.  Allow 3 hours for a complete absorbsion of Sephadex G-50. 
2) Pipette Sephadex G-50 solution in to a gel chromatography column slowly.  
There should be no air bubbles present during packing process. 
3) Allow Sephadex G-50 to settle down gravitationally, and repack the column 
again until desired column height. 
 
4.1.5 Dehydration of Stock Niosome 
1) Clean 50 ml round bottom flask with detergent and dry completely. 
2) Pipette 1.0 ml of stock solution into the round bottom flask. 
3) Pipette 3.0 ml of chloroform into the flask and allow completely mixing for 1-
2 minutes. 
4) After 1-2 minutes, allow nitrogen to flow in at the rate of 3.0 L/min. 
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5) The rotation of the evaporator should be slow and the level of the chloroform 
should remain undisturbed during this process.  The film should be smooth 
and slightly cloudy. 
6) Allow the film to completely dry for 15 min, turn on the vacuum rotary 
evaporator and dry for another 15min while reducing pressure from 1013 
mmbar to approximately less than 100 mmbar. 
7) Turn off the vacuum and quickly allow nitrogen gas to remove oxygen inside 
the flask and close the flask with wrap paper. 
 
4.1.6 Rehydration of Thin Film 
1) Turn on the vacuum evaporator hot bath (60°C) and remove the wrap paper. 
2) Pipette 3.0 ml of CF stock solution into the round bottom flask, place the flask 
back on to the evaporator and lower the flask into the water bath. 
3) Allow hydration for at least 2 hours. 
4) Place the flask in the sonicator bath and allow sonication for approximately 2 
minutes. 
5) Place the solution in a closed lid container and wrap the container with 
aluminum foil. 
 
4.1.7 Gel Exclusion Chromatography Separation 
1) Pipette 0.1 ml of the rehydration sample and place that into the top of the 
column and let the sample settle down for 1 minute. 
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2) Allow the sample to flow through the column.  Note: there should be clear 
color separation. 
3) Collect the sample and wrap each bottle with aluminum foil for further 
analysis. 
 
4.1.8 UV Microscope 
1) Turn on the power supply to both the microscope and UV power generator. 
2) Place a drop on glass slide and place it on the platform of the microscope. 
3) Adjust the microscope to normal mode (visible light) and adjust the 
magnification. 
4) Switch mode form normal mode to UV mode. 
 
4.1.9 Encapsulated Drug Measurement 
1) Turn on the power supply to Perkin Elmer, LS-3B and adjust the excitation to 
“492” and emission to “514”. 
2) Pipette 1.0 ml PBS solution into an empty cuvette and place it in the sample 
holder on the front of fluorometer. 
3) Close the lid, take initial reading and tare the reading using “zero” button. 
4) Add 500 µL of PBS solution follow by 500 µL of the sample. 
5) Place the cuvette back, close the lid and record the intensity. 
6) Remove the cuvette and pipette 20 µL of Triton X-100 into the solution. 
7) Allow complete mixing of the solution using vortex mixer and place the 
cuvette back to take the second measurement. 
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4.1.10 5(6)-Carboxyfluorescein Standardize Curve 
1) Turn on the power supply to Perkin Elmer, LS-3B and adjust the excitation to 
“492” and emission to “514”. 
2) Pipette 1.0 ml PBS solution into an empty cuvette and place it in the sample 
holder on the front of fluorometer. 
3) Close the lid, take initial reading and tare the reading using “zero” button. 
4) Add 500 µL of PBS solution follow by 5 µL of the sample obtained from CF 
stock solution. 
5) Place the cuvette back, close the lid and record the intensity. 
6) Remove the cuvette and pipette 100 µL of PBS into the solution. 
7) Place the cuvette back, close the lid and record the intensity. 
8) Remove the cuvette and pipette another 100 µL of PBS into the solution. 
9) Repeat the same procedure until 2.5 ml of sample in the cuvette. 
10) Repeat this experiment for two more times and take the average values of the 
results. 
11) Construct a standardize curve based on the known concentration with respect 
to their intensities. 
 
4.1.11 Particle Sizing System 780 (PSS 780) 
1) Turn on the power supply to Particle Sizing System and initiate the PSS 
program on the connected computer. 
2) Drain and fill the round bottom flask.  The standard sample volume of H20 
inside this vessel was set to 35 ml. 
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3) Flush the system until the particle count per ml is less than 20 and stop flush. 
4) Pipette 10 µL of the solution obtained from gel exclusion chromatography 
into the vessel and closes the cap. 
5) Start the sample counting by click go one the PSS program and save the 
results into a created software folder. 
6) Repeat the same procedure with another sample. 
 
4.2 Experimental Protocols 
In this study, the following parameters were manipulated (Table 8). 
 
Table 8: The range of values of each variable tested for manipulated parameters in making niosomes 
Manipulated Parameters  Span20 Span 40 Span 60 
Mass per Batch 0.0185-0.0738 gram 0.0198-0.0790 gram 0.0204-0.0816 gram 
Angle of Dehydration 30-60 degree 
Rotation Speed on Rotary 
Evaporator 1-3 revolution/sec 
Nitrogen Dehydration Flowrate 2-5 L/min 
Hydrating Solvent H2O, PBS, PBS-CF 
Hydrating Temperature 40°C and 60°C 
Sonication Time 0-4 min 
 
4.2.1 Determination of Mass per Batch 
1) Clean four 50 ml of round bottom flasks with detergent and dry completely. 
2) Pipette 1.0 ml of Span 60/cholesterol/DCP stock solution into the first flask 
and 3.0 ml of chloroform. 
3) Repeat the procedures listed in Section 4.1.5; observe and record the 
characteristic of the film. 
4) Repeat the procedures described previously and pipette the second flask with 
2.0 ml of Span 60/cholesterol/DCP stock solution and 2.0 ml of chloroform. 
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5) Repeat the procedures described previously and pipette the third flask with 3.0 
ml of Span 60/cholesterol/DCP stock solution and 1.0 ml of chloroform. 
6) Repeat the procedures described previously and pipette the fourth flask with 
4.0 ml of Span 60/cholesterol/DCP stock solution. 
 
4.2.2 Determination of Angle of Evaporation and Speed of Rotation 
1) Clean twelve 50 ml of round bottom flasks with detergent and dry completely. 
2) Pipette 1.0 ml of Span 60 stock solution in twelve flasks and 3.0 ml of 
chloroform. 
3) Repeat the procedures listed in Section 4.1.5, however, the angle of the four 
flasks are as follow 30°, 45°, 52.7° and 60° respectively and the rotation speed 
of 1-1.5 rev/sec. 
4) Observe and record the characteristic of the thin film. 
5) Repeat the same procedures again, however, the rotation speed of the four 
flasks increase to 1.5-2 rev/sec. 
6) Observe and record the characteristic of the thin film. 
7) Repeat the same procedures again, however, the rotation speed of the four 
flasks increase to 2-3 rev/sec. 
8) Observe and record the characteristic of the thin film. 
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4.2.3 Determination of Nitrogen Flow Rate during the Dehydration Process 
1) Clean four 50 ml of round bottom flasks with detergent and dry completely. 
2) Pipette 1.0 ml of Span 60/cholesterol/DCP stock solution in all four flasks and 
3.0 ml of chloroform. 
3) Repeat the procedures listed in Section 4.1.5, however, the nitrogen flowrate 
during the dehydration process increase from 2-5 L/min (1 L/min increment). 
4) Observe and record the characteristic of the thin film. 
 
4.2.4 Effect of Different Hydrating Solvents 
1) Clean nine 50 ml of round bottom flasks with detergent and dry completely. 
2) Pipette 1.0 ml of Span 60/cholesterol/DCP stock solution all nine flasks and 
3.0 ml of chloroform. 
3) Repeat the procedures listed in Section 4.1.5 and Section 4.1.6 with the first 
three flasks, however, the choice of hydrating solvent are H2O, PBS, PBS-CF. 
4) Run the three samples in the PSS-780 with 10 µL injection and record the 
output data prior sonication process. 
5) Repeat the procedures for two more times. 
 
4.2.5 Effect of Different Hydrating Temperatures 
1) Clean six 50 ml of round bottom flasks with detergent and dry completely. 
2) Pipette 1.0 ml of Span 60 stock solution in all six flasks and 3.0 ml of 
chloroform. 
 
 32
3) Repeat the procedures listed in Section 4.1.5 and Section 4.1.6 with PBS-CF 
solution, however, the hydrating temperature is set at 40°C and 60°C. 
4) Run the three samples in the PSS-780 with 10 µL injection and record the 
output data prior sonication process. 
5) Repeat the procedures for two more time. 
 
4.2.6 Effect of Particle Formation during Sonication 
1) Clean three 50 ml of round bottom flasks with detergent and dry completely. 
2) Pipette 1.0 ml of Span 60 stock solution the first flasks and 3.0 ml of 
chloroform. 
3) Pipette 1.0 ml of Span 40 stock solution the first flasks and 3.0 ml of 
chloroform. 
4) Pipette 1.0 ml of Span 20 stock solution the first flasks and 3.0 ml of 
chloroform. 
5) Repeat the procedures listed in Section 4.1.5 and Section 4.1.6 with PBS-CF 
on all three flasks. 
6) Run the three samples in the PSS-780 with 10 µL injection and record the 
output data prior sonication process. 
7) Run the three samples in the PSS-780 with 10 µL injection after sonicate for 1 
minute and record the output data. 
8) Run the three samples again in the PSS-780 with 10 µL injection after 
sonicate for another 1 minute (2 minutes in total) and record the output data. 
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9) Run the three samples in the PSS-780 with 10 µL injection after sonicate for 
another one 1 minute (3 minutes in total) and record the output data. 
10) Run the three samples in the PSS-780 with 10 µL injection after sonicate for 
another one 1 minute (4 minutes in total) and record the output data. 
 
4.3 Quantitative Measurements used in Niosome Characterization 
After optimizing parameters, measurements based on light scattering optical 
microscopy, UV microscopy and fluorometer were made. 
 
4.3.1 Effect of Niosome Vesicles in PBS-CF Solution over Time 
1) Clean a 50 ml of round bottom flask with detergent and dry completely. 
2) Pipette 1.0 ml of Span 60 stock solution in the flasks and 3.0 ml of 
chloroform. 
3) Repeat the procedures listed in Section 4.1.5 and Section 4.1.6 with PBS-CF 
on all three flasks according to the optimized parameters previously 
determined. 
4) Run the three samples in the PSS-780 with 10 µL injection and record the 
output data. 
5) Keep the three sample solutions in close lid container at 4°C (refrigerator). 
6) After one week, run the three samples in the PSS-780 with 10 µL injection 
and record the output data. 
7) Again, keep the three sample solutions in close lid container at 4°C 
(refrigerator). 
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8) After one week (total 2 weeks), run the three samples in the PSS-780 with 10 
µL injection and record the output data. 
 
4.3.2 Separation Pattern Using Gel Exclusion Chromatography 
1) Pipette 1.0 ml, 0.25 ml or 0.10 ml of the Span60/Niosomes sample after 
rehydration into the top of the column. 
2) The column should not be allowed to dry at all time. 
3) Allow the sample to flow through the column.  There should be clear color 
separation based on observation. 
4) Collect sample into separate bottles and wrap each bottle with aluminum foil. 
5) Run each sample collected with PSS-780. 
 
4.3.3 Leakage Studies and Encapsulation Measurement 
1) The sample of Span60/Niosomes, Span40/Niosomes and Span20/Niosomes 
collected after gel exclusion chromatography (previously described in Section 
4.3.2) are kept in the dark at room temperature for the next 9 days. 
2) During this period, these samples are tested for the leakage of CF from the 
niosome vesicles based on the intensity reading from fluorometer (0.5 ml 
injection to the fluorometer+0.5 ml of H20). 
3) Add 20 µL of Triton X-100 and record the changes in the intensity. 
4) To calculate the entrapment efficiency, the intensity measurements of 
Span20/Niosomes, Span 40/Niosomes and Span60/Niosomes produced in 
“Day 0” (before and after breaking niosomes using Triton X-100) were 
recorded and the difference in intensity can be used to calculate the amount of 
mole of CF in the solution.  With the interior volume previously calculated 
based on the result of PSS-780, the final concentration can be calculated. 
5) The entrapment efficiency was calculated based on the following equations: 
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Equation 1, both “diameter” and “particle counted” can be obtained from PSS-
780 ASCII file (Sp60/Niosome in appendix C).  Note, the “particle counted” 
has to be multiplied by the dilution factor. 
Based on the sample collected between 5-10 ml (cumulative volume) after 
GEC, the average values of the changes in intensities (Table 33, Day #0) were 
calculated from Equation 2. 
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Moreover, the number of moles of CF in the niosomes was calculated using 
Equation 3 based on the average intensity obtained in equation #2 and the 
proportionality constant between the intensity and concentration 
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Intensity81060.3  obtained from CF standardized curve (Figure 34). 
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Furthermore, to obtain the number of mole of CF entrapped, the total volume 
tested in the cuvette for the fluorometer (0.5 ml CF sample plus 0.5 ml of 
PBS) was multiplied to the calculated concentration (Equation 3).  Finally, to 
make a comparison the initial mole of CF present inside the niosomes, taking 
the initial concentration of CF (5 mM) and multiplied to the interior volume 
(previously calculated in Equation 1) of the niosomes in a solution assuming 
the initial concentration was 5 mM (Equation 4). 
 
VolumeInterior
ml
L
L
molemoleentrapCFInitial ×××= −
1000
105)( 3   
 Equation 4 
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CHAPTER FIVE:  RESULTS AND DISCUSSION 
 
5.1 Particle Formation 
Essentially, there are several factors which influence particle formation including 
total mass per batch, equipment setup, and dehydration using nitrogen gas and reduced 
pressure, hydrating solvent, hydrating temperature and sonication time.  Using techniques 
described in Section 4, niosome vesicles were formed using 0.0204 gram per batch 
(7.95:7.78:1 molar ratio of span60, cholesterol and dicetyl phosphate respectively), 45° 
angle of evaporation, 1-1.5 rev/sec dehydrating rotation speed, 3 L/min of nitrogen 
flowrate, 40°C hydrating temperature and 2 minute sonication time.  Figure 19 shows a 
microscopic image of spherical vesicles.  Large vesicles with about 10 µm in diameter 
were observed.  Their presence confirms the success of the first step of the process. 
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A)  
 
10 µm 
B)  
 
50 µm  
Figure 19: Microscopic observation of niosome vesicles at (A) 67.1400× , (B)  67.6400×
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5.1.1 Determination of Mass per Batch 
Using the dehydration and rehydration technique, the synthesis of nonionic 
vesicles was achieved using stock solutions of Span60/cholesterol/dicetyl phosphate, 
Span40/cholesterol/dicetyl phosphate and Span20/cholesterol/dicetyl phosphate (Table 
9). 
 
Table 9: Molar ratio of Span/Niosome stock solution (weighted mass in Table 10/MW in Table 2) 
Stock Solution Span (mole) Cholesterol (mole) DCP (mole) 
Sp60/Chol/DCP 7.94 7.78 1.00 
Sp40/Chol/DCP 7.95 7.78 1.00 
Sp20/Chol/DCP 7.95 7.78 1.00 
 
For each batch during dehydration process, there were limits on the amount of 
Span/cholesterol/dicetyl phosphate that could be placed into a 50 ml round bottom flask 
to produce a uniform thin film before rehydration process.  Based on the molar ratio 
given from the literature reports of 7.5:7.5:1 of span, cholesterol (chol) and dicetyl 
phosphate (DCP) respectively [32, 33], the stock solutions were made as follows. 
 
Table 10: Stock solution of Span/Niosome prepared for dehydration process 
Stock Solution Span (g) Chol (g) DCP (g) Total Mass (g) 
Sp60/Chol/DCP 1.0000 0.8800 0.1600 2.0400 
Sp40/Chol/DCP 0.9360 0.8800 0.1600 1.9760 
Sp20/Chol/DCP 0.8060 0.8800 0.1600 1.8460 
 
Since 100 ml of chloroform was used to prepare the stock solution (Table 10), series of 
experiments were carried out to determine the optimal value of mass per batch of 
dehydration.  Based on the observation of the thin film inside 50 ml round bottom flask, 
the optimal mass per batch was 0.0204 grams for Sp60/Niosome, 0.01976 grams for 
Sp40/Niosome and 0.01846 grams for Sp20/Niosome (Table 11). 
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Table 11: Observation of the thin film from different injected volumes of stock solutions 
Sp#/Chol/DCP    
Angle of Evaporation ~52.7°    
Rotation Speed (rev/sec) ~1-1.5    
Nitrogen Flowrate (L/min) 3    
Stock Solution 
Volume of 
Stock 
Solution (ml) 
Volume of 
Chloroform 
(ml) 
Total 
Volume/Batch 
(ml) 
Observation 
After 
Dehydration 
Mass Per 
batch (gram) 
Sp60/Chol/DCP 1.0 3.0 4.0 Smooth thin film 0.0204 
Sp40/Chol/DCP 1.0 3.0 4.0 Smooth thin film 0.0198 
Sp20/Chol/DCP 1.0 3.0 4.0 Smooth thin film 0.0185 
Sp60/Chol/DCP 2.0 2.0 4.0 Aggregation formed 0.0408 
Sp40/Chol/DCP 2.0 2.0 4.0 Aggregation formed 0.0395 
Sp20/Chol/DCP 2.0 2.0 4.0 Aggregation formed 0.0369 
Sp60/Chol/DCP 3.0 1.0 4.0 Aggregation formed 0.0612 
Sp40/Chol/DCP 3.0 1.0 4.0 Aggregation formed 0.0593 
Sp20/Chol/DCP 3.0 1.0 4.0 Aggregation formed 0.0554 
Sp60/Chol/DCP 4.0 0 4.0 Aggregation formed 0.0816 
Sp40/Chol/DCP 4.0 0 4.0 Aggregation formed 0.079 
Sp20/Chol/DCP 4.0 0 4.0 Aggregation formed 0.0738 
 
Consistent with the literature reports [32, 33], the total mass of the process per batch should 
not exceed 0.0250 g per 4.0 ml of total volume of a solution in 50 ml round bottom flask.  
For experiments that exceed 0.0250 g, aggregates usually form at the bottom of the flask 
after dehydration process. 
 
5.1.2 Determination of Angle of Evaporation and Speed of Rotation 
During dehydration process, the position of the round bottom flask and the 
rotation speed of the rotary evaporator were also important factors in producing a smooth 
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uniform thin film.  A series of experiments was conducted to determine the angle of 
dehydration by adjusting the rotary evaporator.  A smooth thin film of Sp60/Niosomes 
was produced for the angle less than 52.7° with the rotation speed of 1-1.5 rev/sec (Table 
12). 
 
Table 12: Observation of the thin film from different angles and rotation speeds 
Sp60/Chol/DCP   
Mass Per Batch (gram) 0.0204   
Nitrogen Flowrate (L/min) 3   
Speed ~30° ~45° ~52.7° ~60° 
1-1.5 
rev/sec 
Smooth thin film, not 
uniform surface 
Smooth thin film, 
not uniform surface 
Smooth thin film, 
uniform surface Aggregation form 
1.5-2 
rev/sec 
Smooth thin film, not 
uniform surface Aggregation form Aggregation form Aggregation form 
2-3 
rev/sec Aggregation form Aggregation form Aggregation form Aggregation form 
 
For experiments that exceed 52.7°, aggregations usually formed at the bottom of the flask 
after dehydration process.  As a result, the angle of evaporation was set at 52.7° and 1-1.5 
rev/sec throughout the experiments. 
 
5.1.3 Determination of Nitrogen Flow Rate during the Dehydration Process 
There were two steps to dehydrating the chloroform, a volatile organic solvent 
used to dissolve a mixture of Span/cholesterol/dicetyl phosphate.  First, a stream of 
nitrogen gas  was passed though the mixture containing Span/cholesterol/dicetyl 
phosphate in a round bottom flask while rotating in the evaporator at a slow flowrate of 3 
L/min (inert gas which was used to prevent oxidation of the thin film).  Table 13 shows 
the effect of nitrogen flow rate on the dehydrated thin film after chloroform evaporated 
slowly upon nitrogen gas contact. 
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Table 13: The effect of nitrogen flow rate on the dehydrated thin film 
Stock Solution 
Mass Per 
batch 
(gram) 
Angle of 
Evaporation 
Rotation 
Speed 
(rev/sec) 
Nitrogen 
Flowrate 
(L/min) 
Observation 
Sp60/Chol/DCP 0.0204 52.7° 1-1.5 2 Smooth thin film 
Sp60/Chol/DCP 0.0204 52.7° 1-1.5 3 Smooth thin film 
Sp60/Chol/DCP 0.0204 52.7° 1-1.5 4 Aggregations formed 
Sp60/Chol/DCP 0.0204 52.7° 1-1.5 5 Aggregations formed 
 
At higher flowrates, non-uniform thin film or aggregation was usually observed at the 
end of each run.  Once a uniform thin film was established using nitrogen gas, a vacuum 
rotary evaporator pulled a vacuum from 1013 mmbar to approximately less than 100 
mmbar in approximately 15 min to ensure a complete removal of chloroform. 
 
5.1.4 Effect of Different Hydrating Solvents 
With an appropriate setup and operating parameters, a series of experiments was 
conducted using a stock solution of Span/cholesterol/dicetyl phosphate, prepared earlier.  
After dehydrating of Span60/cholesterol/dicetyl phosphate, H20, PBS and CF/PBS were 
used as a hydrating solvent.  Using 4.0 ml H20 as a hydrating solvent and hydrating 
temperature of 40°C for 1 hour with 2 minutes sonication time, niosomes distributions 
are determined by Particle Sizing System 780 (Table 14) and microscopic observation of 
Run #1 (Figure 20). 
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Table 14: 3 PSS runs of Sp60/Niosomes hydrating in H20@ 40°C 
Caption: 3 runs on sp60/Niosome in H2O, 10 µL PSS injection, 40°C Hydrating Temperature. 
Sample Run# Run 1 Run 2 Run 3 
Total Particles Sized  291208 303125 299425 
Total Particles in Sample 3034386 3070656 2985267 
Dilution Factor 10.42 10.13 9.97 
Mean (µm) 0.76 0.75 0.77 
Mode (µm) 0.58 0.58 0.58 
Median (µm) 0.62 0.62 0.62 
Average Total Particles in the Sample 3030103 
Standard Deviation 42855 
Average Mean Particles Sized (µm) 0.76 
 
According to Table 14, “Total Particles Sized” coupled with the “Dilution Factor” 
provided the “Total Particles in Sample”.  By taking the result from the 3 runs, “Average 
Total Particles in the Sample” was 3,030,103 and the “Standard Deviation” was 42,855.  
Notice that the total particle counts of Sp60/Niosome lie within one standard deviation 
(3,030,103±42,855).  The “Average Mean Particles Sized” was determined to be 0.76 µm. 
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Figure 20: Run #1, Span60/Niosomes hydrating in H20 
 
Note that particle sizing and quantitative analysis of the vesicle dispersion was done by 
optical light scattering and extinction techniques using a PSS-780.  The instrument counts 
and sizes particles by a combination of light scattering and light extinction technologies, 
but has a lower detection limit of 0.5 µm.  Since all of the calculation was accomplished 
based on particle that are larger than 0.5 µm, there is a small error associated with mean 
particle sizing, counts, counts per ml and the calculated interior volume of niosome 
vesicles.  In other words, the mean particle size would be smaller if PSS-780 detected 
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particles below 0.5 µm, count and count per ml would be higher.  Presently, the 
calculated interior volume of niosomes would be underestimated. 
Similarly, using 4.0 ml PBS as a hydrating solvent and hydrating temperature of 
40°C for 1 hour with 2 minutes sonication time, niosomes distributions are determined by 
Particle Sizing System 780 (Table 15) and microscopic observation (Figure 21). 
 
Table 15: 3 PSS runs of Sp60/Niosomes hydrating in PBS@ 40°C 
Caption: 3 runs on sp60/Niosome in PBS, 10 µL PSS injection, 40°C Hydrating Temperature. 
Sample Run# Run 1 Run 2  Run 3 
Total Particles Sized  316500 302112 319325 
Total Particles in Sample 3206145 3084564 3247535 
Dilution Factor 10.13 10.21 10.17 
Mean (µm) 0.76 0.76 0.75 
Mode (µm) 0.58 0.58 0.58 
Median (µm) 0.62 0.62 0.62 
Average Total Particles in the Sample 3179415 
Standard Deviation 84709 
Average Mean Particles Sized (µm) 0.76 
 
According to Table 15, the “Average Total Particles in the Sample” was 3,179,415 and 
the “Standard Deviation” was 84,709.  Notice that the total particle counts of 
Sp60/Niosome lie within one standard deviation (3,179,415±84,709), similar to the result 
obtained previously using H2O as hydrating solvent.  The “Average Mean Particles 
Sized” was also determined to be 0.76 µm. 
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Figure 21: Run #1, Span60/Niosomes hydrating in PBS 
 
Moreover, using 4.0 ml PBS-CF as a hydrating solvent and hydrating temperature 
of 40°C for 1 hour with 2 minutes sonication time, niosomes distributions are determined 
by Particle Sizing System 780 (Table 16) and microscopic observation (Figure 22). 
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Table 16: 3 PSS runs of Sp60/Niosomes hydrating in PBS-CF@ 40°C 
Caption: 3 runs on sp60/Niosome in PBS-CF, 10 µL PSS injection, 40°C Hydrating Temperature. 
Sample Run# Run 1 Run 2  Run 3 
Total Particles Sized  308518 303102 320114 
Total Particles in Sample 3776260 3603883 3700518 
Dilution Factor 12.24 11.89 11.56 
Mean (µm) 0.75 0.76 0.74 
Mode (µm) 0.58 0.58 0.58 
Median (µm) 0.64 0.64 0.64 
Average Total Particles in the Sample 3693554 
Standard Deviation 86399 
Average Mean Particles Sized (µm) 0.75 
 
Again, according to Table 16, the “Average Total Particles in the Sample” was 3,693,554 
and the “Standard Deviation” was 86,399.  Notice that the total particle counts of 
Sp60/Niosome lie within one standard deviation (3,693,554±86,399), similar to the result 
obtained previously using H2O and PBS as hydrating solvent.  The “Average Mean 
Particles Sized” was also determined to be 0.75 µm. 
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Figure 22: Run #1, Span60/Niosomes hydrating in PBS-CF 
 
Based on the results obtained, niosomes formed using solvents such as H2O, PBS or PBS-
CF yielded similar niosome mean size distribution (0.75-0.76 µm).  The total particles 
detected were in the range of  particles per 10 µL sample.  However, 
there are aggregates formed as a result of low hydrating temperature of 40°C which took 
place at a temperature below the gel to liquid crystal transition temperature of the 
surfactant (suggested temperature of 60°C) 
66 107.3100.3 ×−×
[5].  Overall, niosomes can form using H2O, 
PBS or PBS-CF without significant change in particle size and size distribution.  For the 
following experiments, PBS or PBS-CF will be used as a hydrating solvent. 
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5.1.5 Effect of Different Hydrating Temperatures 
At a higher hydrating temperature above gel-liquid transition temperate, niosomes 
are formed with small amount of aggregations.  Three experiments were performed using 
Span 60 stock solution, 4 ml of PBS for hydration, and 60°C hydrating temperature for 1 
hour and 2 minutes sonication.  Results from Particle Sizing System 780 (Table 17, 
Figure 23) and microscopic observations are shown in Figure 24. 
 
Table 17: 3 PSS runs of Sp60/Niosomes hydrating in PBS-CF@ 60°C 
Caption: 3 runs on sp60/Niosome in PBS-CF, 10 µL PSS injection, 60C Hydrating Temperature. 
Sample Run# Run 1 Run 2 Run 3 
Total Particles Sized  298294 293063 314825 
Total Particles in Sample 3385637 3050786 3714935 
Dilution Factor 11.35 10.41 11.8 
Mean (µm) 1.15 1.16 1.14 
Mode (µm) 0.58 0.58 0.58 
Median (µm) 0.85 0.85 0.85 
Average Total Particles in the Sample 3383786 
Standard Deviation 332078 
Average Mean Particles Sized (µm) 1.15 
 
Based on Table 17, the “Average Total Particles in the Sample” was 3,383,786 and the 
“Standard Deviation” is 332,078.  Notice that the total particle counts of Sp60/Niosome 
lie within one standard deviation (3,383,786±332,078); similar to the result obtained 
previously using PBS-CF as hydrating solvent at 40°C.  However, the “Average Mean 
Particles Sized” has increased from 0.75 µm to 1.18 µm. 
 49
2 4 6 8 10
0
2000
4000
6000
8000
10000
C
ou
nt
 (p
ar
tic
le
s)
Diameter (um)
 Run#1 PBS-CF,60C hydrating Temperature
 Run#2 PBS-CF,60C hydrating Temperature
 Run#3 PBS-CF,60C hydrating Temperature
 
0.50 0.75 1.00 1.25 1.50 1.75 2.00
0
5000
10000
15000
20000
25000
30000
35000
40000
45000
To
ta
l C
ou
nt
 (p
ar
tic
le
s 
pe
r i
nj
ec
tio
n)
Diameter (um)
Figure 23: Run #1, Run#2 and Run#3, Span60/Niosomes hydrating in PBS-CF 
 
 
 
 
 
 
 
 
 
 
  50
A) 400x1.67 magnification 
 
B) 400x1.67 magnification 
 
50 µm 50 µm 
C) 400x1.67 magnification 
 
10 µm 50 µm 
D) 400x6.67 magnification 
Figure 24: Sp60/Niosomes in PBS 60°C (A), (B) and (C) and (D) at different magnifications 
 
In all three experiments, niosomes are formed using PBS at 60°C hydrating temperature 
yielded a larger mean size distribution (1.16-1.19 µm), median (0.85 µm), and mode (0.58 
µm) then niosomes produced at 40°C.  Consistently, three experiments produced very similar 
particle size distribution (Figure 23) and the total particles detected were in the range of 
 particles per 10 µL sample.  Taking PSS-780 results of Run#1 (60°C 
hydrating temperature using PBS-CF) and compared it to Run#1 (40°C hydrating 
temperature using PBS-CF), the change in particle distribution can be observed (Figure 25). 
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Figure 25: Comparison of Sp60/Niosomes particle size distribution at 40°C and 60°C 
 
Based on Figure 25, hydrating temperature played an important role in successfully 
producing niosomes with a higher yield (43% increase in particles counted that are greater 
0.58 µm compared to niosomes produced at 40°C, Appendix A) than those produced below 
gel-liquid transition temperature. 
For different types of surfactant used in this process, a series of experiment were 
carried out using stock solution of Span 20, Span 40 and Span 60.  Using 
dehydration/rehydration method described earlier, niosomes was produced using PBS-CF as 
a hydrating solvent, 60°C hydrating temperature for 1 hour and 2 minute sonication time. 
Niosomes distributions are determined by Particle Sizing System 780 (Table 18, Table 19). 
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Table 18: 3 PSS runs of Sp40/Niosomes hydrating in PBS-CF@ 60°C 
Caption: 3 runs on sp40/Niosome in PBS-CF solution, 10 µL PSS injection 
Sample Run# Run 1 Run 2  Run 3 
Total Particles Sized  302748 323115 314456 
Total Particles in Sample 3184909 3344240 2867839 
Dilution Factor 10.52 10.35 9.12 
Mean (µm) 1.04 1.07 1.05 
Mode (µm) 0.58 0.58 0.58 
Median (µm) 0.85 0.85 0.85 
Average Total Particles in the Sample 3132329 
Standard Deviation 242514 
Average Mean Particles Sized (µm) 1.05 
 
According to Table 18, the result from the 3 runs showed that the “Average Total Particles in 
the Sample” was 3,132,329 and the “Standard Deviation” was 242,517.  Notice that the total 
particle counts of Sp60/Niosome lie within one standard deviation (3,132,329±242,517).  
The “Average Mean Particles Sized” was also determined to be 1.05 µm. 
 
Table 19: 3 PSS runs of Sp20/Niosomes hydrating in PBS-CF@ 60°C 
Caption: 3 runs on sp20/Niosome in PBS-CF solution, 10 µL PSS injection 
Sample Run# Run 1 Run 2 Run 3 
Total Particles Sized  294893 294582 313483 
Total Particles in Sample 2842769 3196215 3605055 
Dilution Factor 9.64 10.85 11.5 
Mean (µm) 0.83 0.87 0.84 
Mode (µm) 0.58 0.58 0.58 
Median (µm) 0.85 0.85 0.85 
Average Total Particles in the Sample 3214679 
Standard Deviation 381478 
Average Mean Particles Sized (µm) 0.85 
 
According to Table 19, the result from the 3 runs showed that the “Average Total Particles in 
the Sample” was 3,214,679 and the “Standard Deviation” was 381,478.  Notice that the total 
particle counts of Sp60/Niosome lie within one standard deviation (3,214,679±381,478).  
The “Average Mean Particles Sized” was also determined to be 0.85 µm. 
Furthermore, taking PSS-780 results of Run#1 of Sp60/Niosomes, Run#1 of 
Sp40/Niosomes and Run#1 of Sp20/Niosomes and plotted on the same graph, the change in 
particle distribution can be observed (Figure 26). 
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Figure 26: Comparison of Sp 20, Sp40 and Sp60/Niosomes using PBS-CF 
 
Based on Table 17, Table 18, Table 19, Span60/Niosomes have the largest “Average Total 
Particles” of 3,383,786 particles per 10µL injection and the “Average Mean Particle Sized” 
of 1.18 µm as compared to Span40/Niosome (3,132,329 counts per 10 µL, 1.05 µm) and 
Span20/Niosome (3,214,679 counts per 10 µL, 0.85 µm).  For Span60/Niosomes, there are 
greater numbers of particles are formed in the range of 1-2 µm.  Span 20/Niosome and Span 
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40/Niosome formed smaller particles are formed closer to or less than 1 µm.  Overall, Span 
60/Niosome demonstrated a good candidate for drug delivery applications. 
 
5.1.6 Effect of Particle Formation during Sonication 
Sonication time also played an important role in the formation of niosomes.  A series 
of experiments was conducted to determine the effects of sonication on mean size 
distribution and total population after sonication.  First, Span 60/Niosomes were produced 
using techniques described earlier using PBS-CF as hydrating solvent.  After rehydrating 
process, 10 µL of sample was injected to Particle Sizing System 780 to record the particle 
distribution at time zero.  The rest of the sample was then placed on the sonicator and, for 
every minute, 10 µL of sample was drawn out to record the particle distribution.  Below are 
results Span60/Niosomes formed 0-4 min sonication (Table 20, Figure 27). 
 
Table 20: Sp60/Niosomes particle counts and size distribution from 0-4 minutes sonication time 
Caption: 0-4 min sonication sp60/Niosome in PBS-CF solution, 10 µL PSS injection PSS 
Sample Sonication Time 0 min 1 min 2 min 3 min 4 min 
Total Particles Sized  256938 309428 353337 328783 313347 
Total Particles in Sample 1264135 2803418 3731239 3501539 2976797 
Dilution Factor 4.92 9.06 10.56 10.65 9.50 
Mean (µm) 1.21 1.17 1.13 1.00 0.95 
Mode (µm) 0.58 0.58 0.58 0.58 0.58 
Median (µm) 0.77 0.74 0.70 0.68 0.67 
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Figure 27: PSS results, Sp60/Niosomes particle distribution from 0-4 minutes sonication time 
 
According to Figure 27, at time zero, Span60/Niosomes had the largest particle 
distribution where particle are formed in multilamellar structure.  After every minute of 
sonication, particle distribution below approximately 1 µm was shifting upward and particle 
distribution greater than 1 µm was shifting downward as a result of small lamella formation. 
Having observed a well defined particle formation pattern where particle distribution 
shift to the left (small lamella formation) with respect to sonication time, similar experiments 
were conducted with Span20/Niosomes and Span40/Niosome.  Below were results 0-4 
minutes sonication (Table 21, Figure 28, Table 22, Figure 29). 
Table 21: Sp20/Niosomes particle counts and size distribution from 0-4 minutes sonication time 
Caption: 0-4 min sonication sp20/Niosome in PBS-CF solution, 10 µL PSS injection PSS 
Sample Sonication Time 0 min 1 min 2 min 3 min 4 min 
Total Particles Sized  272578 296068 294893 298637 273703 
Total Particles in Sample 999875 2304347 2843782 3186408 2552591 
Dilution Factor 3.67 7.78 9.64 10.67 9.33 
Mean (µm) 1.11 0.90 0.83 0.82 0.79 
Mode (µm) 0.58 0.58 0.58 0.58 0.58 
Median (µm) 0.76 0.70 0.68 0.67 0.66 
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Figure 28: PSS results, Sp20/Niosomes particle distribution from 0-4 minutes sonication time 
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Table 22: Sp40/Niosomes particle counts and size distribution from 0-4 minutes sonication time 
Caption: 0-4 min sonication sp40/Niosome in PBS-CF solution, 10 µL PSS injection PSS 
Sample Sonication Time 0 min 1 min 2 min 3 min 4 min 
Total Particles Sized  314758 302748 324115 313710 303525 
Total Particles in Sample 762212 2272110 3410857 3700323 3084138 
Dilution Factor 2.42 7.50 10.52 11.80 10.16 
Mean (µm) 1.17 1.11 1.04 0.97 0.97 
Mode (µm) 0.58 0.58 0.58 0.58 0.58 
Median (µm) 0.86 0.72 0.72 0.70 0.70 
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Figure 29: PSS results, Sp40/Niosomes particle distribution from 0-4 minutes sonication time 
 
According to Figure 28 and Figure 29, similar to experiment perform using 
Span60/Niosomes, Span20/Niosomes and Span40/Niosomes had the largest particle 
distribution where particles were formed in multi-lamellar structure at time zero.  After 
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every minute of sonication, particle distribution below approximately 1 µm was shifting 
upward and particle distribution greater than 1µm was shifting downward as a result of 
small-lamellar formation. 
According to Figure 30, the total counts of Span20/Niosomes, Span40/Niosomes 
and Span60/Niosomes increased as samples were sonicated from 0 to approximately 2-3 
minutes.  However, for sonication times greater than 3 minutes, particle counts decreased 
as a result of particles that are formed less than 0.5 µm (below the detection limit of PSS-
780).  For optimization of niosome production, a 2 minute sonication time was set for all 
experiments.  The particle average diameter also decreased with sonication time as a result 
of small-lamellar formation (Figure 31).  For Span20/Niosomes, Span40/Niosomes and 
Span60/Niosomes, particles average diameter decreased from 1.11-0.79 µm, 1.17-0.97 µm 
and 1.21-0.95 µm respectively (Figure 31). 
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Figure 30: PSS total particle counts of Sp20, Sp40 and Sp60/Niosomes from 0-4 minutes sonication 
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Figure 31: PSS average particle distribution of Sp20, Sp40 and Sp60/Niosomes from 0-4 minutes 
sonication 
 
Figure 32 demonstrated the size reduction of prepared Span 60/Niosomes after 2 
minutes sonication based on microscopic observation with hemocytometer slice for a clear 
comparison. 
 
A) 
 
50 µm 
50 µm 
B) 
Figure 32: Sp60/Niosomes observation A) before sonication and B) after sonication 
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5.2 5(6)-Carboxyfluorescein 
A calibration curve relating intensity to concentration was established to 
determine entrapment efficiency of CF inside niosomes. 
 
5.2.1 5(6)-Carboxyfluorescein Standard Curve 
During rehydration, solution containing CF and sodium hydroxide (NaOH) in 
PBS is used as a drug model.  In general, a direct measurement of quantities of CF 
encapsulated and leaked out of niosomes can be calculated using standardized curve 
measurement.  Briefly, a series of known CF concentrations were prepared from the CF 
stock solution.  The intensity reading for each concentration using the fluorometer is 
shown in Table 23, Figure 33 and Figure 34. 
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Table 23: CF intensities with respect to known concentrations 
Stock Solution 
Concentration (mol/L) 
Volume of Stock 
Solution Injection (ml) 
Volume of PBS 
injection (ml) 
Total Volume 
(ml) Average Intensity Concentration (mol/L) 
5.00E-03 1 0 1 2.3 5.00E-03 
5.00E-04 1 0 1 47.5 5.00E-04 
5.00E-05 1 0 1 835.5 5.00E-05 
5.00E-06 1 0 1 556.3 5.00E-06 
5.00E-07 0.9 0.1 1 176.3 4.50E-07 
5.00E-07 0.9 0.2 1.1 159.7 4.09E-07 
5.00E-07 0.9 0.3 1.2 140.6 3.75E-07 
5.00E-07 0.9 0.4 1.3 119.4 3.46E-07 
5.00E-07 0.9 0.5 1.4 108 3.21E-07 
5.00E-07 0.9 0.6 1.5 100.3 3.00E-07 
5.00E-07 0.9 0.7 1.6 93.4 2.81E-07 
5.00E-07 0.9 0.8 1.7 88 2.65E-07 
5.00E-07 0.9 0.9 1.8 82.8 2.50E-07 
5.00E-07 0.9 1 1.9 78.6 2.37E-07 
5.00E-07 0.9 1.1 2 74.5 2.25E-07 
5.00E-07 0.9 1.2 2.1 70.7 2.14E-07 
5.00E-07 0.9 1.3 2.2 67.1 2.05E-07 
5.00E-07 0.9 1.4 2.3 64.3 1.96E-07 
5.00E-07 0.9 1.5 2.4 61.7 1.88E-07 
5.00E-07 0.9 1.6 2.5 59.2 1.80E-07 
5.00E-07 0.9 1.7 2.6 56.8 1.73E-07 
5.00E-07 0.9 1.8 2.7 54.8 1.67E-07 
5.00E-07 0.3 0.7 1 62.8 1.50E-07 
5.00E-07 0.3 0.8 1.1 55.3 1.36E-07 
5.00E-07 0.3 0.9 1.2 47.1 1.25E-07 
5.00E-07 0.3 1 1.3 42.1 1.15E-07 
5.00E-07 0.3 1.1 1.4 39 1.07E-07 
5.00E-07 0.3 1.2 1.5 36.2 1.00E-07 
5.00E-07 0.3 1.3 1.6 34 9.38E-08 
5.00E-07 0.3 1.4 1.7 31.9 8.82E-08 
5.00E-07 0.3 1.5 1.8 30.2 8.33E-08 
5.00E-07 0.3 1.6 1.9 28.6 7.89E-08 
5.00E-07 0.3 1.7 2 27.1 7.50E-08 
5.00E-07 0.3 1.8 2.1 25.8 7.14E-08 
5.00E-07 0.3 1.9 2.2 24.5 6.82E-08 
5.00E-07 0.3 2 2.3 23.4 6.52E-08 
5.00E-07 0.3 2.1 2.4 22.5 6.25E-08 
5.00E-07 0.3 2.2 2.5 21.6 6.00E-08 
5.00E-07 0.3 2.3 2.6 20.7 5.77E-08 
5.00E-08 0.9 0.1 1 18.8 4.50E-08 
5.00E-08 0.9 0.2 1.1 16.4 4.09E-08 
5.00E-08 0.9 0.3 1.2 14 3.75E-08 
5.00E-08 0.9 0.4 1.3 12.6 3.46E-08 
5.00E-08 0.9 0.5 1.4 11.6 3.21E-08 
5.00E-08 0.9 0.6 1.5 10.8 3.00E-08 
5.00E-08 0.9 0.7 1.6 10.2 2.81E-08 
5.00E-08 0.9 0.8 1.7 9.6 2.65E-08 
5.00E-08 0.9 0.9 1.8 9 2.50E-08 
5.00E-08 0.9 1 1.9 8.5 2.37E-08 
5.00E-08 0.9 1.1 2 8.1 2.25E-08 
5.00E-08 0.9 1.2 2.1 7.7 2.14E-08 
5.00E-08 0.9 1.3 2.2 7.4 2.05E-08 
5.00E-08 0.9 1.4 2.3 7 1.96E-08 
5.00E-08 0.3 0.7 1 6.4 1.50E-08 
5.00E-08 0.3 0.8 1.1 5.5 1.36E-08 
5.00E-08 0.3 0.9 1.2 4.7 1.25E-08 
5.00E-08 0.3 1 1.3 4.2 1.15E-08 
5.00E-08 0.3 1.1 1.4 3.8 1.07E-08 
5.00E-08 0.3 1.2 1.5 3.6 1.00E-08 
5.00E-08 0.3 1.3 1.6 3.4 9.38E-09 
5.00E-08 0.3 1.4 1.7 3.1 8.82E-09 
5.00E-08 0.3 1.5 1.8 3 8.33E-09 
5.00E-08 0.3 1.6 1.9 2.8 7.89E-09 
5.00E-08 0.3 1.7 2 2.7 7.50E-09 
5.00E-08 0.3 1.8 2.1 2.5 7.14E-09 
5.00E-08 0.3 1.9 2.2 2.4 6.82E-09 
5.00E-08 0.3 2 2.3 2.3 6.52E-09 
5.00E-08 0.3 2.1 2.4 2.2 6.25E-09 
5.00E-08 0.3 2.2 2.5 2.1 6.00E-09 
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Figure 33: Standard curve of florescence intensity vs. concentration of CF 
 
According to Figure 34, a linear relationship between intensity and CF 
concentration was observed in a low concentration range of mol/l.  However, 
at a higher concentration of CF, the relative intensity decreased as a result of CF’s “self 
quenching” described earlier.  Since a linear relationship was observed at lower end of 
the CF concentration, fitting the data points was accomplished using a trend-line program 
(Figure 34 and Equation 5). 
71050 −×−
 
(mole/L) ionconcentratC andintensity I where1060.3 8 ==×= CI . 
 Equation 5 
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Therefore, dilution of encapsulated CF with Span/Niosomes before proceeding to the 
measurement of CF using fluorometer was necessary to prevent a misleading reading 
from “self quenching” phenomena. 
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Figure 34: Standard curve of florescence intensity vs. concentration of CF (linear fit) 
 
 Furthermore, to determine the variability between CF batches (stock solution), the 
intensities readings of CF stock solution were recorded and compared between batch #1 
and batch #2.  Batch #2 was made and tested for their consistency using the same 
procedures of that batch #1 (Figure 35). 
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Figure 35: Comparison of CF stock solution batch #1 and batch #2 based on concentration and 
intensity 
 
Notice that the concentration and their intensity of the two stock solutions are in the 
range of ±5% of intensity values obtained in batch #2 using batch #1 as a standard 
solution.  As a result, new stock solution was used in the experiment without creating a 
new standard curve. 
 
5.3 Quantitative Measurements used in Niosome Characterization 
With an appropriate setup (mass per batch, angle of evaporation, rotation speed 
and nitrogen flowrate during dehydration process) and operating parameters (types of 
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hydrating solvents, hydrating temperature and sonication time), a series of experiments 
were conducted using PBS-CF rehydrating solution of Span20/Niosomes, 
Span40/Niosomes and Span60/Niosomes.  Quantitative measurements based on light 
scattering optical microscopy, UV microscopy, fluorometer and PSS-780 were 
conducted.  First, the stability of niosome vesicles in PBS-CF solution over time is 
observed using PSS-780.  Second, separating of unencapsulated CF using GEC is 
characterized using PSS-780 and fluorometer.  Thirdly, after GEC, CF entrapped inside 
niosomes is observed under UV microscope.  Lastly, the amount of CF entrapped inside 
niosomes can be determined using fluorometry and previously obtained standard CF 
curve (Section 5.2). 
 
5.3.1 Effect of Niosome Vesicles in PBS-CF Solution over Time 
To determine their stability, Span60/Niosome batch using PBS-CF hydrating 
solvent with 2 minutes sonication were kept separately for 2 week period.  The stability 
of the vesicles over time is demonstrated in Figure 36.  Dispersions of Span60/CF 
niosomes were monitored for 2 weeks for changes in particle size distribution and mean 
particle size using Particle Sizing System 780 (Table 24 and Figure 36). 
 
Table 24: Comparison of Sp60/Niosomes particle counts and mean size of particles 0-14 days 
Caption: span 60 Day 0-Day 14 10 µL injection PBS-CF Day 0 Day 1 Day 14 
Total Particles Sized 312943 314825 325961 
Total Particles in Sample 3311120 3714429 3650685 
Dilution Factor 10.58 11.8 14.27 
Fluid Volume Sampled (ml) 60 60 60 
Mean (µm) 1.15 1.19 1.24 
Mode (µm) 0.58 0.58 0.58 
Median (µm) 0.85 0.85 0.85 
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Figure 36: Sp60/Niosomes particle size distribution 14 days after rehydrating process 
 
The increase in particle counts in the range of greater than 2 µm for Day 1 after 
rehydrating process as compared to Day 0 was computed to be 9% and 29% for Day 14 
(Appendix B).  The shift in mean particle size (Table 24) may be due to aggregation. 
 
5.3.2 Separation Pattern Using Gel Exclusion Chromatography 
Next, Span20, Span40 or Span60/Niosomes solutions were placed on top of the 
gel exclusion chromatography described earlier to separate out the unencapsulated dye.  
 68
Investigations of how this column operates for Span60/Niosomes at different sample size 
of 0.1 ml, 0.25 ml and 1.0 ml were performed (Table 25, Table 26 and Table 27). 
The data in the first and second column in Table 25, Table 26 and Table 27 
represents the volume of sample collected and cumulative volume of sample.  The third 
column shows the volume injection of collected sample into PSS-780.  The data in the 
forth and the fifth column (“Count” and “Count/ml”) was results obtained from PSS-780.  
Finally, the last column was calculated based on the product of the “Counts/ml (PSS-
780)” and “Volume of Sample collected” to obtain the number of particles in the sample.  
Furthermore, the sum of all of the particles in the last column was compared to the initial 
count.  Percent recoveries of the 3 experiments were reported (Table 25, Table 26 and 
Table 27). 
 
Table 25: GEC separation of unencapsulated CF from 0.25 ml injection of Sp60/Niosomes 
Span60/Niosomes 0.25 ml injection 
Volume of 
Sample 
Collected (ml) 
Cumulative volume 
(ml) 
PSS volume 
Inject (ml) Count (PSS) 
Count/ml 
(PSS) Total Count 
3 3 0.5 134947 269894 809682 
1 4 0.5 302707 605414 605414 
1 5 0.5 5015185 10030370 10030370 
1 6 0.25 4361015 17444060 17444060 
1 7 0.25 2880461 11521844 11521844 
1 8 0.25 1664320 6657280 6657280 
1 9 0.25 1238906 4955624 4955624 
1 10 0.25 911021 3644084 3644084 
1 11 0.25 751149 3004596 3004596 
5 16 0.5 103618 207236 1036180 
10 26 0.5 75156 150312 1503120 
      
   Final Count 61212254 
   Initial Count 76284375 
   % of Recovery ~80% 
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Table 26: GEC separation of unencapsulated CF from 1.00 ml injection of Sp60/Niosomes 
Span60/Niosomes 1.00 ml injection 
Volume of 
Sample 
Collected (ml) 
Cumulative 
volume (ml) 
PSS volume 
Inject (ml) Count (PSS) 
Count/ml 
(PSS) Total Count 
3 3 0.5 189916 379832 1139496 
1 4 0.5 191779 383558 383558 
1 5 0.1 91992 919920 919920 
1 6 0.01 488153 48815300 48815300 
1 7 0.01 549349 54934900 54934900 
1 8 0.01 446928 44692800 44692800 
1 9 0.01 307263 30726300 30726300 
1 10 0.01 223464 22346400 22346400 
1 11 0.01 130354 13035400 13035400 
5 16 0.01 34913 3491300 17456500 
10 26 0.01 5363 536300 5363000 
      
   Final Count 239813574 
   Initial Count 321476353 
   % of Recovery ~75% 
 
Table 27: GEC separation of unencapsulated CF from 0.10 ml injection of Sp60/Niosomes 
Span60/Niosomes 0.10 ml injection 
Volume of 
Sample 
Collected (ml) 
Cumulative 
volume (ml) 
PSS volume 
Inject (ml) Count (PSS) 
Count/ml 
(PSS) Total Count 
3 3 0.5 153279 306558 919673 
1 4 0.5 281163 562325 562325 
1 5 0.5 4221766 8443531 8443531 
1 6 0.5 3528291 7056582 7056582 
1 7 0.5 1926008 3852015 3852015 
1 8 0.5 1432339 2864678 2864678 
1 9 0.5 938226 1876452 1876452 
1 10 0.5 762494 1524988 1524988 
1 11 0.5 598329 1196658 1196658 
5 16 0.5 57164 114327 571636 
10 26 0.5 19562 39125 391248 
      
   Final Count 29259786 
   Initial Count 33976389 
   % of Recovery ~86% 
 
Notice that the initial and final counts were decreased in all three cases (76,284,375 to 
61,212,254 counts in 0.25 ml injection, 321,476,353 to 239,813,574 counts in 1.00ml 
injection and 33,976,389 to 29,259,786 counts in 0.10ml injection).  It was estimated that 
80% recovery was obtained in the 0.25 ml injection, 75% recovery was obtained in the 
1.00 ml injection and 86% recovery was obtained in the 0.10 ml injection.  As a result, 
0.10 ml of sample injection was set for all gel exclusion chromatography separation 
processes. 
Based on result obtained from Table 25, Table 26 and Table 27, the separation 
pattern can be observed through the particle counts per volume collected (Figure 37). 
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Figure 37: GEC counts per ml vs. cumulative volume collected 
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Based on Table 25, Table 26 and Table 27 and Figure 37, most of the particles exited the 
gel exclusion chromatography column between 4-26 ml volume collected with the 
maximum amount of Span60/Niosomes around 6ml sample collection for 0.25 ml 
injection, 7 ml sample collection for 1.00 ml injection and 5ml sample collection for 0.10 
ml injection.  Overall, for the following gel exclusion chromatography separation 
experiment, the samples were collected at 5-10 ml cumulative volume where the highest 
particle counts were observed. 
Furthermore, based on the collected particle mean diameter of Span60/Niosomes, 
highest particle distribution around 5-15 cumulative volume were observed in both 0.25 
ml sample injection and 0.10 ml sample injection (Table 28 and Figure 38).  For 1.00 ml 
sample injection, niosomes did not exit the column at a particular distribution (only 
increased in mean particle diameter). 
 
Table 28: Particle size distribution of Sp60/Niosomes sample collected after GEC 
GEC Results (PSS-780): Mean Diameter for various Injection of Span60/Niosomes 
Volume of Sample 
Collected (ml) 
Cumulative volume 
(ml) 
1.00ml 
Injection (µm) 
0.25ml 
Injection (µm) 
0.10ml 
Injection (µm) 
3 3 0.76 0.90 0.91 
1 4 0.77 0.91 0.91 
1 5 0.77 0.91 0.92 
1 6 0.93 0.94 0.91 
1 7 0.94 0.93 0.94 
1 8 0.93 0.94 0.94 
1 9 0.94 0.96 0.94 
1 10 0.95 0.95 0.96 
1 11 0.96 0.97 0.98 
5 16 1.05 0.95 0.97 
10 26 1.09 0.94 0.93 
 
Notice that the particle mean diameters determined by PSS-780 are less than 1 µm in 
both 0.25 ml sample injection and 0.10 ml sample injection (Table 28).  This is because, 
during the separation process, diluting media provide trace of small impurities that 
resulting in the shift in particle distribution to a lower range. 
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Figure 38: GEC, mean diameter vs. cumulative volume 
 
 By taking the result from PSS-780 obtained previously for 0.1 ml injection GEC, 
similar relationships between particle counts per ml and CF intensity measurements using 
a fluorometer were observed (Table 29 and Figure 39). 
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Table 29: Comparison of counts per ml and background intensity vs. cumulative volume of sample 
Cumulative volume (ml) Count/ml (PSS) Recorded Intensity Average Intensity 
3 306558 0.0 0.0 0.0 0.0 
4 562325 0.1 0.1 0.1 0.1 
5 8443530 7.6 7.7 7.8 7.7 
6 7056580 7.6 7.7 7.6 7.6 
7 3852020 6.2 6.1 6.3 6.2 
8 2864680 4.8 4.8 5.0 4.9 
9 1876450 3.1 3.5 3.3 3.3 
10 1524990 1.5 1.7 1.3 1.5 
11 1196660 0.7 0.8 0.7 0.7 
16 114327 0.1 0.1 0.1 0.1 
26 39125 0.1 0.0 0.0 0.0 
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Figure 39: Comparison of counts per ml and background intensity vs. cumulative volume of sample 
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Notice that particle counts and CF intensity had a highest peak at 5 ml collection and 
highest distribution between 5-10 ml of sample collection.  Based on collected sample, 
0.5 ml of Span20/Niosomes, Span40/Niosomes and Span60/Niosomes (0.1 ml injection 
into gel exclusion chromatography separation) were injected to PSS-780 and result was 
observed (Table 30, Table 31, Table 32 and Figure 40). 
 
Table 30: 2 PSS runs of Sp20/Niosomes after GEC (5-10 ml cumulative volume and 0.5 ml injection) 
Caption: 2 runs on sp20/Niosome Draw #2 after GEC 
Sample Run# Run 1 (0.5 ml injection) Run 2 (0.5 ml injection) 
Total Particles Sized  287422 266019 
Total Particles in Sample 1655168 1920591 
Dilution Factor 5.76 7.22 
Mean (µm) 0.94 0.95 
Mode (µm) 0.58 0.58 
Median (µm) 0.66 0.67 
 
Table 31: 2 PSS runs of Sp40/Niosomes after GEC (5-10 ml cumulative volume and 0.5 ml injection) 
Caption: 2 runs on sp40/Niosome Draw #2 after GEC 
Sample Run# Run 1 (0.5 ml injection) Run 2 (0.5 ml injection) 
Total Particles Sized  292319 297572 
Total Particles in Sample 1446979 1234924 
Dilution Factor 4.95 4.15 
Mean (µm) 0.95 1.02 
Mode (µm) 0.58 0.58 
Median (µm) 0.71 0.74 
 
Table 32: 2 PSS runs of Sp60/Niosomes after GEC (5-10 ml cumulative volume and 0.5 ml injection) 
Caption: 2 runs on sp60/Niosome Draw #2 after GEC 
Sample Run# Run 1 (0.5 ml injection) Run 2 (0.5 ml injection) 
Total Particles Sized  282137 279057 
Total Particles in Sample 1690219 2434632 
Dilution Factor 5.99 8.72 
Mean (µm) 0.99 0.98 
Mode (µm) 0.58 0.58 
Median (µm) 0.76 0.74 
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Figure 40: Comparison of Run#1 from Sp20, Sp40 and Sp60/Niosomes formation after GEC 
 
Based on Figure 40, there are similarities between the plots behaviors obtained prior to 
gel exclusion chromatography separation as described earlier (Figure 26).  Furthermore, 
particles size distribution was obtained in the range of 0.94-0.99 µm with the particles 
count in the range of counts per 0.5 ml or approximately 
 vesicle counts per ml/per mass of surfactant (Table 11, Table 30, Table 
31 and Table 32). 
66 103.2108.1 ×−×
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5.3.3 UV Microscopic Observation 
 Following the previous process, samples collected between 5-10 ml after running 
through gel exclusion chromatography separation, were examined under the light/UV 
microscope to demonstrate that niosomes have encapsulated CF.  A small droplet of 
collected sample was placed on a slide under the microscope and observed at 67.1400 ×  
magnification.  Presence of CF inside Span60/Nisomes was observed in Figure 41. 
 
 
A) 
 
B) 
Figure 41: Observation of Sp60/Niosomes under A) regular light scattering mode and B) UV mode 
 
Span60/Nisosomes were observed under regular light scattering mode (A).  Switching off 
to the UV mode, bright fluorescent green dots were observed (B).  Based on this 
observation, it was clear that Span60/Niosomes encapsulated CF inside the vesicle 
membrane and maintained their structural integrity inside a solution. 
 
5.3.4 Leakage Studies 
 Sample of Span20/Niosomes, Span40/Niosomes and Span60/Niosomes collected 
between 5-10 ml after gel exclusion chromatography separation were kept for 9 days in 
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the dark for leakage analysis.  Starting from day zero, 0.5 ml of a sample and 0.5 ml of 
PBS was placed in the cuvette to take an initial reading from fluorometer.  Then, 20 µL 
of Triton X-100 was added into the sample to disrupt the membrane to obtain the final 
reading.  For the following days, the same procedures were repeated to determine the 
leakage from niosomes (Figure 42 and Table 33). 
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Figure 42: Stability of Sp20, Sp40 and Sp60/Niosomes, day 0 to day 9 
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Table 33: Leakage study of Sp20, Sp40 and Sp60/Niosomes from day 0 to day 9 
Membrane permeability of various Niosomes, Day # 0-9 using CF intensity measurement 
Span 20 Span 40 Span 60 
Day 
Initial Intensity Final Intensity Initial Intensity Final Intensity Initial Intensity Final Intensity 
15.20 22.90 12.50 16.70 9.70 14.80 
15.40 22.30 13.20 17.20 8.20 13.20 0 
15.80 22.80 14.80 19.10 8.20 13.10 
Average 15.47 22.67 13.50 17.67 8.70 13.70 
Span 20 Span 40 Span 60 
Day 
Initial Intensity Final Intensity Initial Intensity Final Intensity Initial Intensity Final Intensity 
15.40 21.40 13.70 17.50 11.10 15.70 
15.00 21.10 14.40 18.70 11.10 16.40 1 
15.70 21.60 15.20 19.30 9.90 14.80 
Average 15.37 21.37 14.43 18.50 10.70 15.63 
Span 20 Span 40 Span 60 
Day 
Initial Intensity Final Intensity Initial Intensity Final Intensity Initial Intensity Final Intensity 
15.20 21.70 12.20 16.60 9.40 14.00 
15.80 22.70 11.60 15.30 9.60 14.70 2 
16.00 22.90 12.30 16.20 9.50 14.30 
Average 15.67 22.43 12.03 16.03 9.50 14.33 
Span 20 Span 40 Span 60 
Day 
Initial Intensity Final Intensity Initial Intensity Final Intensity Initial Intensity Final Intensity 
15.10 21.10 12.70 17.30 8.80 13.60 
14.20 20.40 11.80 15.70 9.10 14.10 3 
14.60 20.70 12.00 16.60 9.60 14.90 
Average 14.63 20.73 12.17 16.53 9.17 14.20 
Span 20 Span 40 Span 60 
Day 
Initial Intensity Final Intensity Initial Intensity Final Intensity Initial Intensity Final Intensity 
13.50 21.10 10.90 15.50 7.80 12.10 
13.70 20.40 10.80 15.60 7.80 12.10 7 
13.90 20.70 10.20 14.40 8.80 13.30 
Average 13.70 20.73 10.63 15.17 8.13 12.50 
Span 20 Span 40 Span 60 
Day 
Initial Intensity Final Intensity Initial Intensity Final Intensity Initial Intensity Final Intensity 
13.70 19.60 10.60 13.40 8.20 13.50 
13.20 19.20 10.70 13.60 8.50 13.70 9 
13.50 19.40 10.50 13.20 8.40 13.60 
Average 13.47 19.40 10.60 13.40 8.37 13.60 
 
 
In Figure 42, the initial value represents the background fluorescence of the sample, and 
the final intensity of the fluorescence signal after the vesicles were disrupted using Triton 
X-100.  Apparent fluctuation in the results may have been caused by inherent variability 
of injection volumes (  by volume for pipette injections at 10 µL).  The overall 
trends of these data indicated that the vesicles show very little leakage over 9 days period. 
%5±
Based on the average intensity increased (Figure 43) after adding Triton X-100 
and the result obtained from the ASCII file output from Particle Sizing System 780, 
entrapment efficiency was calculated based on the Equation 1, Equation 2, Equation 3 
and Equation 4. 
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Figure 43: Average intensity increased for Sp20, Sp40 and Sp60/Niosomes from day 0 to day 9 
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The result of the calculation is shown below: 
 
Table 34: Summary of Sp20, Sp40 and Sp60/Niosomes CF entrapment percentage 
Surfactant Interior volume (cm3) 
Average 
Intensity 
(Day #0) 
CF entrap 
(mole) 
Actual CF 
(mole) 
Concentration 
(mol/l) 
Percent 
Entrapment 
Sp20 8.23E-06 7.2 2.01E-11 4.11E-11 2.44E-03 48.8% 
Sp40 4.71E-06 4.2 1.16E-11 2.36E-11 2.47E-03 49.3% 
Sp60 4.43E-06 5.0 1.39E-11 2.21E-11 3.15E-03 62.9% 
 
The concentration of CF entrapped in niosomes was calculated to be 48.8-62.9% of the 
original 5 mM.  The concentration of CF inside niosomes was estimated to be 2.44-3.15 
mM for Span 60, Span40 and Span20.  Consistent with literatures [34, 31, ]60 , the increased 
size of the lipophilic alkyl chain of surfactants (Span 60, Span40 and Span20) has shown 
to produce larger vesicles which would explain the increasing entrapment capability of 
the vesicles. 
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CHAPTER SIX:  CONCLUSIONS 
 
 The present study has partially optimized synthesis technique for niosome as a 
drug carrier system and characterized its ability to encapsulate drug model 5(6)-
carboxyfluorescein (CF) and leakage studies.  Vesicles were formed by the combination 
of surfactants (Span 20, Span40 and Span60), cholesterol and dicetyl phosphate using 
appropriate setup and operating parameters.  This included optimization parameters such 
as mass per batch, angle of evaporation, dehydration nitrogen flowrate, hydrating 
solvents, hydrating temperature and sonication time (Table 35). 
 
Table 35: Summary of optimized parameters in making Span/niosome system 
  Flask Size Molar Ratio 
Mass Per 
Batch 
Angle of 
Evaporation 
Nitrogen 
Flowrate 
Hydrating 
Solvent 
Hydrating 
Temperature. 
Sonication 
Time 
Sp60 50ml 7.94:7.78:1.0 0.02040 ~52.7degree ~1-1.5 rev/sec PBS/PBS-CF 60C 2 min 
Sp40 50ml 7.94:7.78:1.1 0.01976 ~52.7degree ~1-1.5 rev/sec PBS/PBS-CF 60C 2 min 
Sp20 50ml 7.94:7.78:1.2 0.01846 ~52.7degree ~1-1.5 rev/sec PBS/PBS-CF 60C 2 min 
 
After gel exclusion chromatography separation (0.1 ml injection and 5-10 ml cumulative 
volume collected after running the sample), niosome vesicles were observed under both 
light microscope and UV microscope to demonstrate CF entrapment.  They are stable in 
solution over time (approximately 9 days) and exhibit low leakage over the time.  Vesicle 
size was dependent on choice of surfactant where Span 60 surfactant has shown to 
produce the largest particle size distribution (0.99 µm).  The highest entrapment 
percentage based on calculated particle volume using Particle Sizing System 780 and CF 
measurement from fluorometer was obtained from Span60/Nisomes (62.9%) follow by 
Span40/Niosome (49.3%) and Span20/Niosome (48.8%).  Typical concentrations of 
vesicle per ml/per mass of surfactant used were in the range of .  Based 
on the choice of surfactants (Span 20, Span 40 or Span 60), the increase in size of alkyl 
chain in making niosomes (increase in HLB values of Span 20, Span 40 and Span 60 
respectively according to Table 2) has shown to produce larger vesicles which would 
explain the increase in entrapment capability. 
81079.146.1 ×−
 
6.1 Future Work: Using Niosomes in Cardiovascular Therapy 
In this present study, CF is used specifically for this model and has been 
entrapped by niosome vesicles.  For future study, repeated investigation is necessary 
when using a chosen drug, and depending on the molecular structure, as well as the 
physical and chemical properties of the drugs and their respective synthesis techniques, 
characterization protocols and quantitative measurements may be necessary. 
In reference to atherosclerotic plaque, it has become apparent that inflammation 
plays a key role in the plaque development [60, , , , ]61 62 63 64 .  It has also been recognized that 
pentameric protein in liver, fibrinogen, leukocyte counts, inflammatory cytokines, 
adhesion molecules and makers of leukocyte activation are involved in the 
atherosclerosis process [61, 62, 63].  Many researchers have developed and tested the 
effectiveness of cardiovascular drug such as statins, ACE-Inhibition/Angiotensin II 
receptor blockade and peroxisome proliferator activated receptors α (PPAR-α) to reduce 
inflammatory biomarker in atherosclerosis [ ]65 .  Some of these are clinically available, 
others are available for experimentation.  Although these drugs have shown promising 
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results, drug delivery systems may increase the effectiveness by delivering active 
ingredients, minimized the side effects by inhibiting uptake by the immune system and 
lowering toxicity to unaffected tissues. 
 
6.1.1 Statins 
Clinically, inhibition of this pathway by statins, potent inhibitors of 3-hydroxy-3-
methyl-CoA (HMG-CoA) reductase, has been shown to reduce plasma levels of LDL 
cholesterol and several clinical trials with this group of drugs have demonstrated a 
remarked reduction in monocyte-endothelial interaction in atherosclerosis during plaque 
progression [ , , , ]66 67 68 69 .  Several datas also suggested that the benefits of drug 
interventions such as statin therapy is the most effective among those with elevated 
inflammatory markers and mediators such as CRP, cytokines, cellular adhesion molecule 
levels, platelet activation factors of vascular inflammation [ , , , , , , , , , , ]70 71 72 73 74 75 76 77 78 79 80 .  
Other studies have shown that lipid-lowering therapy using statin-derivative therapy 
changes plaque morphology and leads to coronary plaque stabilization [ , , ]81 82 83 .  Above 
all are beneficial results of this class of drug, however, recent focus on the effects of 
statins that are more frequently observed at higher doses and in combination with other 
lipid lowering drugs may need careful consideration in individuals at risk of adverse drug 
reactions based on genetic variability of an individual and the analysis of genetic variants 
of drug therapy [ , ]84 85 . 
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6.1.2 ACE-Inhibition/Angiotensin II Receptor Blockade 
 Angiotensin converting enzyme (ACE) inhibitors has been shown to reduce the 
development of atherosclerosis in hypercholesterolemic animals across a wide range of 
species and has proven to be effective in reducing the surface area of the lesions [ , , ]86 87 88 .  
Although the mechanism for these effects has not been well defined, it was assumed that 
both Angiotensin II suppression and interference with the breakdown of bradykinin, 
nanopeptides which help increase vascular permeability, dilate blood vessels, contract 
non-vascular smooth muscle and may cause pain, are involved.  In one study, by blocking 
the degradation of bradykinin, ACE inhibitors potentiate the ability of bradykinin to 
reduce blood pressure and stimulate the release of tissue-type plasminogen activator from 
the vasculature which resulted in removing the blockage [ ]89 .  Another study in a 
genetically hypercholesterolemic rabbit model showed that suppression of the renin-
angiotensin system by ACE inhibition causes comparable inhibition of aortic 
atherosclerosis and mild reduction of blood pressure [ ]90 .  Finally, synthesized or non-
sulfhydryl ACE inhibitor, enalapril, injected into cholesterol-fed rabbits has been shown 
to significantly reduce the percent plaque areas in the aortas [ ]91 . 
 
6.1.3 PPAR-α Agonist 
 Several animal studies have shown that fibrate treatment for ligands, peroxisome 
proliferator-activated receptor α (PPAR-α), leads to a reduction of the coronary events 
associated with factors related to atherosclerosis.  One study has shown that the effective 
treatment with the PPAR-α agonist on the development of atherosclerotic lesions in 
apolipoprotein (apo) E-deficient mice resulted in the reduction of aortic cholesterol 
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content [ ]92 .  Other studies have shown that PPAR-α (Wy 14643) partially inhibit ox-LDL 
and cytokine such as TNF-α and reduce transforming growth factor β (TGF-β), highly 
expressed in the lesions, which suggested beneficial effects on the vascular wall of 
atherosclerotic plaque [ , , , , , ]93 94 95 96 97 98 .  Finally, the influence of PPAR-α activators on 
intracellular cholesterol homeostasis was investigated and found to decrease the 
cholesterol ester (CE):free cholesterol (FC) ratio as a result of blocking TNF-α induced 
CE formation [ , , ]99 100 101 .  Above all, PPAR-α has shown a positive result in animal 
experimentation, however, this particular drug has not been proven effective in some 
experiments such as severely aggravates hypercholesterolemia and accelerates the 
development of atherosclerosis in mice lacking apolipoprotein E [ ]102 . 
 
6.2 Future Work: Background on Targeting Atherosclerotic Plaque 
The following subsection backgrounds provide important clues of how 
atherosclerotic plaque developed.  In other words, the chemokines that are normally 
associated with the biological processes leading to the plaque formation may open a way 
to specifically target these niosome vesicles, where progressing plaques occur. 
 
6.2.1 Mechanisms of leukocyte Adhesion (Clues for Targeting Atherosclerotic 
Plaque) 
High levels of LDL have been shown to accelerate atherosclerosis in experimental 
animals and in humans.  Introducing LDL to endothelial cells has a significant impact on 
the plaque growth and number of monocyte adhesion [ , ]103 104 .  This effect was described 
as an “oxidative process” or the release of oxygen free radicals in the arterial lining to 
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oxidized LDL, triggering atherosclerosis.  As a result, excess oxidized LDL (ox-LDL) 
transfers into endothelial cell membrane, serving as a basis for cholesterol build up on the 
arterial wall and atherosclerotic plaque.  Moreover, due to excess ox-LDL, the viscosity 
of the plasma increased to create disturbed flow and increased shear stress which could 
explain the preference of leukocyte adhesion particularly at the vessel orifices and 
bifurcations.  Although, it should be noted that specific plaque adhesion prefers the lower 
shear stress neighborhood over the higher shear stress neighborhood, in the region in 
which the flow exhibits a change in stress rate.  Furthermore, ox-LDL was found to 
promote adhesion effect of leukocytes to the endothelium as a result of chemotactic 
activities based on “oxidative process” [ ]105  and oxidized LDL exert direct chemotactic 
effects on monocytes [ ]106  in a common feature in early atherogenesis [ ]107 . 
In vivo, studies have shown that significant amounts of ox-LDL were present in 
human plasma and atherosclerotic lesions, inducing mRNA for the human monocyte 
chemoattraction protein-12 (MCP-1) which ultimately increases the monocytes adhesion 
to endothelial cells [ ]108 .  The details of these studies showed that ox-LDL stimulates the 
rolling, tethering and adhering of circulating leukocytes to the endothelium in arterioles 
and venules and to aortic endothelium [107].  For example, leukocyte adhesion in response 
to ox-LDL was associated with increased permeability of fluorescent stained 
macromolecules across endothelium, in a rat mesenteric model [ ]109 .  Beside chemotactic 
signals generated by the dysfunction of the endothelium, incorporation of ox-LDL into 
monocyte/macrophage lipid bilayer by phagocytosis process enhanced the adhesivity due 
to physical changes in the membrane [ , ]110 111 .  Several researchers have found expression 
such as leukocyte function-associated antigen 1 (LFA-1), Mac-1 and p150,95, adhesion 
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receptors belong to the β2-integrin family using several types of monoclonal antibodies.  
For example, ox-LDL induced leukocyte adhesion to venular and arteriolar endothelium 
was shown to be prevented significantly by pretreating with the monoclonal antibody to 
the CD11b subunit of Mac-1 [ , , , ]112 113 114 115 .  This observation showed that anti-Mac-1 
inhibited adhesion of all leukocytes and suggested the role of monocyte adhesion, 
activation and release of mediators to recruitment of more leukocytes, including 
lymphocytes to endothelium.  Moreover, self adhesions of circulating leukocytes further 
increase the size of atherosclerotic plaque could be considered as the contribution of the 
chemotactic attraction, adhesion and emigration. 
Many studies have shown that vascular cell adhesion molecule type 1 (VCAM-1), 
intercellular adhesion molecule-1 (ICAM-1), P-selectin and E-selectin on atherosclerotic 
lesion [ , ]116 117 .  These expressions promoted the adhesion of both leukocytes and 
lymphocytes through binding receptor of the β1 and β2-integrin family.  Rolling, 
tethering and adhering of circulating leukocytes to the endothelium in arterioles and 
venules and to aortic endothelium were observed as a result of β1 and β2-integrin family 
receptors.  For example, immunohistochemical staining in aortas of normal chow-fed 
wild-type mice and rabbits, VCAM-1 and ICAM-1 were expressed by endothelial cells in 
regions predisposed to atherosclerotic lesion formation predominantly by endothelium on 
early and by intimal cells in more advanced lesions [112]. 
 The overall process of cellular adhesion molecules may take several hours in vivo 
and can be summarized into three steps.  First, P-selectin and E-selectin on the 
endothelium and L-selectin on the surface of leukocytes slowed down leukocytes as they 
passed through the vessel and roll on the surface of the endothelial before it became 
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completely stopped.  Secondly, the slowed leukocytes have enough time to respond to 
chemokines signaling molecules on the endothelial surface, and then engaged in the 
cellular adhesion molecules using leukocyte’s integrins (β1 and β2) to cause firm 
adhesion and initiate migration. 
 
6.3 Summary 
Based on the following reviews, using these structural dynamic carriers such as 
niosomes, the chemokines (Anti-ICAM-1 and Anti-VCAM-1) which played an important 
role in biological processes leading to the plaque formation may open a way to 
specifically target these niosome vesicles, where progressing plaques occur.  Following 
the attachment and release of cardiovascular drugs, it is believed that this process may 
help create an anatomical and physiological barrier to plaque growth (plaque 
stabilization) with little or no further treatments. 
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Appendix A 
Comparison between niosomes produced at 40°C and 60°C with the increase in particles 
size distribution that are greater ~0.58 µm.  Calculating result are shown below: 
 
 
Mean Particle Distribution Niosomes 40C Niosomes 60C Difference (60C-40C) 
0.57609 174019 78839 0 
0.58392 119138 94428 0 
0.59185 110076 91666 0 
0.59989 102447 60827 0 
0.60804 101525 86875 0 
0.6163 47054 55844 8790 
0.62467 91757 81697 0 
0.63315 41366 59046 17680 
0.64175 86775 57535 0 
0.65047 93398 53708 0 
0.65931 44149 53709 9560 
0.66826 81009 56379 0 
0.67734 75568 56608 0 
0.68654 38917 53997 15080 
0.69586 79076 26286 0 
0.70532 73335 53205 0 
0.7149 34218 27748 0 
0.72461 62799 51709 0 
0.73445 60556 24116 0 
0.74443 59915 47955 0 
0.75454 26422 22932 0 
0.76479 48871 48171 0 
0.77517 44545 23725 0 
0.7857 44416 44166 0 
0.79638 39963 20223 0 
0.80719 17792 40912 23120 
0.81816 33671 20661 0 
0.82927 32513 41053 8540 
0.84054 31253 20313 0 
0.85195 27474 36894 9420 
0.86352 24281 36321 12040 
0.87525 24190 38390 14200 
0.88714 23915 18525 0 
0.89919 20650 34800 14150 
0.91141 18782 32732 13950 
0.92379 29037 33687 4650 
0.93633 17043 35103 18060 
0.94905 14989 30959 15970 
0.96194 13660 41660 28000 
0.97501 12979 27449 14470 
0.98825 17148 26148 9000 
1.00168 10066 24036 13970 
1.01528 15027 36137 21110 
1.02907 9335 23545 14210 
1.04305 12674 33724 21050 
1.05722 12797 31937 19140 
1.07158 11476 21106 9630 
1.08614 9575 28895 19320 
1.10089 6478 26438 19960 
1.11584 8919 26729 17810 
1.131 7989 24879 16890 
1.14636 7578 23038 15460 
1.16193 6837 21447 14610 
1.17772 9036 20976 11940 
1.19371 6305 27455 21150 
1.20993 4948 18448 13500 
1.22636 5179 18309 13130 
1.24302 4806 24006 19200 
1.2599 6095 16015 9920 
1.27702 4522 21392 16870 
1.29436 3901 20681 16780 
1.31194 5245 18205 12960 
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1.32976 3396 17276 13880 
1.34783 4663 17003 12340 
1.36613 3832 16162 12330 
1.38469 4901 15121 10220 
1.4035 3343 13823 10480 
1.42256 4153 16973 12820 
1.44189 3854 12684 8830 
1.46147 2751 12051 9300 
1.48132 3360 14770 11410 
1.50144 3395 13205 9810 
1.52184 2850 10110 7260 
1.54251 2722 11882 9160 
1.56346 2347 12107 9760 
1.5847 2283 10493 8210 
1.60622 2669 10159 7490 
1.62804 2480 10220 7740 
1.65015 2129 9159 7030 
1.67257 2098 8538 6440 
1.69529 2366 8136 5770 
1.71832 2447 8347 5900 
1.74166 1665 9215 7550 
1.76531 2134 7594 5460 
1.78929 2117 8847 6730 
1.81359 1506 8506 7000 
1.83823 1695 7915 6220 
1.8632 1888 6178 4290 
1.88851 1829 7499 5670 
1.91416 1339 6899 5560 
1.94016 1398 6448 5050 
1.96651 1437 6797 5360 
1.99322 1696 6876 5180 
2.0203 1415 7535 6120 
2.04774 738 5388 4650 
2.07555 849 5589 4740 
2.10375 696 5296 4600 
2.13232 775 6235 5460 
2.16129 722 5022 4300 
2.19064 501 5711 5210 
2.2204 625 4725 4100 
2.25056 496 5446 4950 
2.28113 573 4813 4240 
2.31211 882 5122 4240 
2.34352 651 5421 4770 
2.37535 533 4283 3750 
2.40762 613 4833 4220 
2.44032 444 4934 4490 
2.47347 671 4841 4170 
2.50706 460 4820 4360 
2.54112 525 4525 4000 
2.57563 490 4310 3820 
2.61062 412 4682 4270 
2.64608 567 3957 3390 
2.68202 513 4023 3510 
2.71845 499 4209 3710 
2.75538 480 3930 3450 
2.7928 469 4439 3970 
2.83074 328 4058 3730 
2.86919 466 3746 3280 
2.90816 487 4027 3540 
2.94766 455 3435 2980 
2.9877 384 3884 3500 
3.02828 317 3757 3440 
3.06942 526 3966 3440 
3.11111 455 3825 3370 
3.15337 508 3338 2830 
3.1962 459 3829 3370 
3.23961 379 3599 3220 
3.28362 488 3668 3180 
3.32822 407 2887 2480 
3.37343 366 3426 3060 
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3.41925 385 3445 3060 
3.46569 458 3208 2750 
3.51277 389 3009 2620 
3.56048 256 3136 2880 
3.60885 365 3345 2980 
3.65787 372 2902 2530 
3.70755 251 2821 2570 
3.75791 365 2775 2410 
3.80896 246 3206 2960 
3.86069 413 2743 2330 
3.91313 322 2742 2420 
3.96629 361 2491 2130 
4.02016 353 2743 2390 
4.07477 273 2453 2180 
4.13012 304 2854 2550 
4.18622 311 2571 2260 
4.24308 290 2590 2300 
4.30071 245 2295 2050 
4.35913 350 2470 2120 
4.41834 252 2082 1830 
4.47835 187 2237 2050 
4.53918 273 2013 1740 
4.60084 409 1899 1490 
4.66333 190 2070 1880 
4.72668 200 2110 1910 
4.79088 212 2342 2130 
4.85595 277 1777 1500 
4.92191 153 2143 1990 
4.98877 339 1949 1610 
5.05653 270 1880 1610 
Total Particle (40C) 2420917 Particle Increased 1046680 
Percent Increased 43% 
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Comparison between niosomes produced at Day 0, Day 1 and Day 14 with the increase in 
particles size distribution that is greater ~2 µm.  Calculating results are shown below: 
 
 
Mean Particle 
Distribution Niosomes (Day 0) Niosomes (Day 1) Niosomes (Day 14) 
Difference (Day1-
Day 0) 
Difference 
(Day14-Day 0) 
2.0203 6730 6340 6910 0 180 
2.04774 5550 6250 5620 700 70 
2.07555 5270 6200 5880 930 610 
2.10375 5270 7050 5320 1780 50 
2.13232 6200 6010 6370 0 170 
2.16129 4690 6690 4900 2000 210 
2.19064 5650 5760 5770 110 120 
2.2204 4720 6150 4700 1430 0 
2.25056 5620 5550 5530 0 0 
2.28113 4460 5540 4540 1080 80 
2.31211 5320 5590 5270 270 0 
2.34352 5280 4800 4810 0 0 
2.37535 4330 5480 4500 1150 170 
2.40762 5380 4860 4550 0 0 
2.44032 4780 5490 4810 710 30 
2.47347 4690 5020 4570 330 0 
2.50706 4210 4870 4950 660 740 
2.54112 4690 4770 4030 80 0 
2.57563 4310 4710 4190 400 0 
2.61062 4350 4610 4490 260 140 
2.64608 3900 4600 4130 700 230 
2.68202 3950 4290 3920 340 0 
2.71845 3870 3960 4120 90 250 
2.75538 3880 4280 4030 400 150 
2.7928 3790 3760 4120 0 330 
2.83074 3500 3900 3700 400 200 
2.86919 3610 4120 3850 510 240 
2.90816 4050 3340 4600 0 550 
2.94766 3400 4050 3300 650 0 
2.9877 3930 3460 4190 0 260 
3.02828 3440 3530 3730 90 290 
3.06942 4040 3670 4260 0 220 
3.11111 4120 3070 4030 0 0 
3.15337 3170 3250 3590 80 420 
3.1962 3540 3080 4050 0 510 
3.23961 3670 3080 3870 0 200 
3.28362 3560 2600 4220 0 660 
3.32822 3010 3150 3270 140 260 
3.37343 3400 2950 4140 0 740 
3.41925 3170 3080 3780 0 610 
3.46569 3280 3120 3840 0 560 
3.51277 3320 3320 3860 0 540 
3.56048 3750 2730 4210 0 460 
3.60885 3170 2770 3880 0 710 
3.65787 3180 2860 3900 0 720 
3.70755 3110 2810 3350 0 240 
3.75791 2750 2970 3610 220 860 
3.80896 3030 2600 4390 0 1360 
3.86069 2610 2670 3590 60 980 
3.91313 3160 2390 4350 0 1190 
3.96629 2560 2620 3790 60 1230 
4.02016 2910 2350 4440 0 1530 
4.07477 2470 2480 4010 10 1540 
4.13012 2850 2250 4280 0 1430 
4.18622 2390 1960 4730 0 2340 
4.24308 2470 2270 3730 0 1260 
4.30071 2680 1980 4040 0 1360 
4.35913 2590 2080 4080 0 1490 
4.41834 2430 2090 3740 0 1310 
4.47835 2460 1790 4030 0 1570 
4.53918 1870 2070 3260 200 1390 
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4.60084 2050 1850 4220 0 2170 
4.66333 2160 1880 3510 0 1350 
4.72668 1940 2140 3640 200 1700 
4.79088 2510 1810 3980 0 1470 
4.85595 1990 1900 3260 0 1270 
4.92191 2010 2110 3210 100 1200 
4.98877 2120 1610 3800 0 1680 
5.05653 1880 1960 3270 80 1390 
5.12522 1770 1460 3640 0 1870 
5.19483 1980 1640 2940 0 960 
5.26539 1800 1640 3230 0 1430 
5.33691 1560 1460 3270 0 1710 
5.40941 1440 1560 3020 120 1580 
5.48288 1470 1470 2840 0 1370 
5.55736 1360 1410 3040 50 1680 
5.63284 1430 1460 2330 30 900 
5.70936 1560 1350 2340 0 780 
5.78691 1240 1260 2170 20 930 
5.86551 1230 1360 1970 130 740 
5.94518 1170 1310 2160 140 990 
6.02594 990 1290 1760 300 770 
6.10779 960 890 1820 0 860 
6.19075 870 1010 1550 140 680 
6.27484 990 950 1810 0 820 
6.36007 920 1110 1660 190 740 
6.44646 730 920 1390 190 660 
6.53403 640 880 1270 240 630 
6.62278 710 980 1670 270 960 
6.71274 600 850 1330 250 730 
6.80392 470 960 1210 490 740 
6.89634 570 940 1300 370 730 
6.99001 500 820 1180 320 680 
7.08496 420 910 1020 490 600 
7.18119 560 720 1050 160 490 
7.27873 430 750 1040 320 610 
7.3776 410 810 1010 400 600 
7.47781 420 730 1080 310 660 
7.57939 430 720 950 290 520 
7.68234 370 720 850 350 480 
7.78669 280 750 860 470 580 
7.89246 280 600 880 320 600 
7.99966 340 520 900 180 560 
8.10832 300 370 770 70 470 
8.21846 270 530 810 260 540 
8.33009 390 490 820 100 430 
8.44324 280 470 800 190 520 
8.55792 260 440 630 180 370 
8.67417 320 590 800 270 480 
8.79199 240 430 720 190 480 
8.91141 250 390 740 140 490 
9.03246 170 430 530 260 360 
9.15515 280 320 700 40 420 
9.2795 170 350 540 180 370 
9.40555 270 430 510 160 240 
9.5333 170 370 690 200 520 
9.6628 190 350 590 160 400 
9.79405 230 340 660 110 430 
9.92708 120 240 490 120 370 
10.06192 130 0 490 0 360 
10.19859 230 0 0 0 0 
Total Particle (Day 0) 285370 Particle Increased 25390 81880 
Percent Increased 9% 29% 
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Appendix C 
Sample calculation of PSS ASCII-file from PSS: total volume calculation with 
Span60/Niosomes after gel exclusion column. 
 
Below is the equation for calculating the total interior volume of niosomes from 0.56~20 
µm. 
 
PSS-780 ASCII files for Span20/Niosomes after GEC (0.5 ml injection) 
Particle Sizing 
Systems, Inc.         
Santa Barbara, 
Calif., USA         
Model 780 
AccuSizer         
Caption: 
span20 cf 1st 
draw 5 ml--0.5 
ml inj         
File Name =   711s2ge2.001  
Time Date 
=  
7/11/2003 
11:44      
Sensor Model:   LE400-0.5 SUM  S/N:  8910 Cal.  File:   0008910s.sns   
Elapsed Time 
of Data 
Collection =   60 Sec.       
Background 
File =  NONE        
Total # Part. 
Sized 
(>=Thres. 0.53 
um ) =  266019        
Calculated 
Total No. of 
Particles in 
Sample =  1920591        
Dilution Factor 
=  7.22        
Fluid Volume 
Sampled =  60 ml  
No. of 
Channels =  512     
NUM-WT 
Mean =  0.95 um  Mode =  0.58 um  Median =  0.67  
VOL-WT 
Mean =  8.27 um  Mode =  12.66 um  Median =  8.1  
         
Summary of 
Detailed 
Distribution, 
Weightings         
Diameter # Part. Cum Num  Num % Vol % 
Cum Num 
% Vol Num % # Part. 
Interior 
Volume 
(microns) Sized  >=Diam.   >=Diam. >=Diam.  w/dilution ml 
0.53851 8158 266019 3.067 0.059 100 100 59064 4.8295E-09 
0.54583 8787 257861 3.303 0.066 96.933 99.941 63618 5.41689E-09 
0.55324 5994 249074 2.253 0.047 93.63 99.875 43397 3.84764E-09 
0.56076 9729 243080 3.657 0.079 91.377 99.829 70438 6.50334E-09 
0.56837 10314 233351 3.877 0.087 87.72 99.75 74673 7.1789E-09 
0.57609 10122 223037 3.805 0.089 83.843 99.662 73283 7.33626E-09 
0.58392 11370 212915 4.274 0.104 80.038 99.573 82319 8.58139E-09 
0.59185 10632 201545 3.997 0.102 75.763 99.469 76976 8.35578E-09 
0.59989 6732 190913 2.531 0.067 71.767 99.367 48740 5.5093E-09 
0.60804 9679 184181 3.638 0.1 69.236 99.3 70076 8.24829E-09 
0.6163 5906 174502 2.22 0.064 65.598 99.2 42759 5.24092E-09 
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0.62467 8562 168596 3.219 0.096 63.377 99.136 61989 7.9116E-09 
0.63315 5866 160034 2.205 0.069 60.159 99.04 42470 5.64416E-09 
0.64175 5676 154168 2.134 0.069 57.954 98.971 41094 5.68692E-09 
0.65047 5251 148492 1.974 0.067 55.82 98.902 38017 5.47849E-09 
0.65931 5110 143241 1.921 0.067 53.846 98.836 36996 5.55171E-09 
0.66826 5329 138131 2.003 0.073 51.925 98.768 38582 6.02864E-09 
0.67734 5127 132802 1.927 0.073 49.922 98.695 37119 6.03977E-09 
0.68654 4624 127675 1.738 0.069 47.995 98.621 33478 5.67221E-09 
0.69586 2256 123051 0.848 0.035 46.256 98.552 16333 2.88165E-09 
0.70532 4453 120795 1.674 0.072 45.408 98.517 32240 5.92309E-09 
0.7149 2371 116342 0.891 0.04 43.734 98.445 17166 3.28401E-09 
0.72461 4331 113971 1.628 0.076 42.843 98.406 31356 6.24652E-09 
0.73445 1979 109640 0.744 0.036 41.215 98.33 14328 2.97214E-09 
0.74443 3671 107661 1.38 0.07 40.471 98.293 26578 5.74107E-09 
0.75454 1821 103990 0.685 0.036 39.091 98.224 13184 2.96547E-09 
0.76479 3737 102169 1.405 0.077 38.407 98.188 27056 6.33705E-09 
0.77517 1720 98432 0.647 0.037 37.002 98.111 12453 3.03708E-09 
0.7857 3379 96712 1.27 0.076 36.355 98.074 24464 6.21292E-09 
0.79638 1470 93333 0.553 0.034 35.085 97.998 10643 2.81459E-09 
0.80719 2997 91863 1.127 0.073 34.533 97.964 21698 5.97518E-09 
0.81816 1642 88866 0.617 0.041 33.406 97.891 11888 3.40898E-09 
0.82927 2987 87224 1.123 0.079 32.789 97.85 21626 6.45744E-09 
0.84054 1324 84237 0.498 0.036 31.666 97.771 9586 2.98058E-09 
0.85195 2532 82913 0.952 0.072 31.168 97.735 18332 5.93531E-09 
0.86352 2414 80381 0.907 0.072 30.216 97.663 17477 5.89239E-09 
0.87525 2480 77967 0.932 0.077 29.309 97.591 17955 6.30355E-09 
0.88714 1258 75487 0.473 0.04 28.377 97.515 9108 3.32962E-09 
0.89919 2235 74229 0.84 0.075 27.904 97.474 16181 6.15984E-09 
0.91141 2109 71994 0.793 0.074 27.063 97.399 15269 6.05278E-09 
0.92379 1977 69885 0.743 0.072 26.271 97.326 14313 5.90831E-09 
0.93633 2086 67908 0.784 0.079 25.528 97.254 15103 6.4914E-09 
0.94905 1882 65822 0.707 0.074 24.743 97.175 13626 6.09851E-09 
0.96194 2500 63940 0.94 0.103 24.036 97.101 18100 8.4357E-09 
0.97501 1598 61440 0.601 0.068 23.096 96.998 11570 5.61489E-09 
0.98825 1483 59842 0.557 0.066 22.495 96.93 10737 5.42599E-09 
1.00168 1385 58359 0.521 0.064 21.938 96.864 10027 5.27684E-09 
1.01528 2071 56974 0.779 0.1 21.417 96.8 14994 8.21627E-09 
1.02907 1322 54903 0.497 0.066 20.639 96.7 9571 5.46139E-09 
1.04305 1841 53581 0.692 0.096 20.142 96.633 13329 7.91966E-09 
1.05722 1688 51740 0.635 0.092 19.45 96.537 12221 7.56146E-09 
1.07158 1135 50052 0.427 0.064 18.815 96.445 8217 5.29428E-09 
1.08614 1592 48917 0.598 0.094 18.389 96.381 11526 7.73282E-09 
1.10089 1410 47325 0.53 0.087 17.79 96.287 10208 7.13162E-09 
1.11584 1407 45915 0.529 0.09 17.26 96.2 10187 7.41032E-09 
1.131 1306 44508 0.491 0.087 16.731 96.11 9455 7.16256E-09 
1.14636 1287 43202 0.484 0.089 16.24 96.023 9318 7.34986E-09 
1.16193 1184 41915 0.445 0.086 15.756 95.934 8572 7.04091E-09 
1.17772 1094 40731 0.411 0.082 15.311 95.848 7921 6.77455E-09 
1.19371 1497 39637 0.563 0.117 14.9 95.766 10838 9.65285E-09 
1.20993 990 38140 0.372 0.081 14.337 95.648 7168 6.64742E-09 
1.22636 974 37150 0.366 0.083 13.965 95.568 7052 6.81005E-09 
1.24302 1207 36176 0.454 0.107 13.599 95.485 8739 8.78777E-09 
1.2599 843 34969 0.317 0.078 13.145 95.378 6103 6.39106E-09 
1.27702 1097 34126 0.412 0.105 12.828 95.3 7942 8.66038E-09 
1.29436 1024 33029 0.385 0.102 12.416 95.195 7414 8.41787E-09 
1.31194 958 32005 0.36 0.1 12.031 95.093 6936 8.20058E-09 
1.32976 944 31047 0.355 0.102 11.671 94.993 6835 8.41451E-09 
1.34783 835 30103 0.314 0.094 11.316 94.891 6045 7.75049E-09 
1.36613 754 29268 0.283 0.089 11.002 94.796 5459 7.2876E-09 
1.38469 778 28514 0.292 0.095 10.719 94.708 5633 7.83023E-09 
1.4035 766 27736 0.288 0.098 10.426 94.613 5546 8.02792E-09 
1.42256 863 26970 0.324 0.115 10.138 94.515 6248 9.41802E-09 
1.44189 658 26107 0.247 0.091 9.814 94.4 4764 7.47755E-09 
1.46147 602 25449 0.226 0.087 9.567 94.31 4358 7.12366E-09 
1.48132 751 24847 0.282 0.113 9.34 94.223 5437 9.25388E-09 
1.50144 680 24096 0.256 0.106 9.058 94.11 4923 8.72509E-09 
1.52184 514 23416 0.193 0.083 8.802 94.004 3721 6.86764E-09 
1.54251 606 22902 0.228 0.103 8.609 93.921 4387 8.43129E-09 
1.56346 625 22296 0.235 0.11 8.381 93.818 4525 9.05477E-09 
1.5847 615 21671 0.231 0.113 8.146 93.708 4453 9.27798E-09 
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1.60622 525 21056 0.197 0.1 7.915 93.595 3801 8.2473E-09 
1.62804 502 20531 0.189 0.1 7.718 93.495 3634 8.21176E-09 
1.65015 463 20029 0.174 0.096 7.529 93.395 3352 7.88658E-09 
1.67257 470 19566 0.177 0.101 7.355 93.299 3403 8.33658E-09 
1.69529 442 19096 0.166 0.099 7.178 93.198 3200 8.16378E-09 
1.71832 429 18654 0.161 0.1 7.012 93.099 3106 8.251E-09 
1.74166 485 18225 0.182 0.118 6.851 92.999 3511 9.71335E-09 
1.76531 385 17740 0.145 0.098 6.669 92.88 2787 8.02899E-09 
1.78929 425 17355 0.16 0.112 6.524 92.783 3077 9.22929E-09 
1.81359 425 16930 0.16 0.117 6.364 92.671 3077 9.61044E-09 
1.83823 452 16505 0.17 0.129 6.204 92.554 3272 1.06433E-08 
1.8632 318 16053 0.12 0.095 6.035 92.424 2302 7.79727E-09 
1.88851 376 15735 0.141 0.117 5.915 92.33 2722 9.60026E-09 
1.91416 358 15359 0.135 0.116 5.774 92.213 2592 9.5182E-09 
1.94016 363 15001 0.136 0.122 5.639 92.097 2628 1.00498E-08 
1.96651 324 14638 0.122 0.114 5.503 91.975 2346 9.34051E-09 
1.99322 313 14314 0.118 0.114 5.381 91.861 2266 9.39609E-09 
2.0203 334 14001 0.126 0.127 5.263 91.747 2418 1.04407E-08 
2.04774 274 13667 0.103 0.108 5.138 91.62 1984 8.91892E-09 
2.07555 304 13393 0.114 0.125 5.035 91.512 2201 1.03041E-08 
2.10375 275 13089 0.103 0.118 4.92 91.387 1991 9.70627E-09 
2.13232 327 12814 0.123 0.146 4.817 91.269 2367 1.20183E-08 
2.16129 254 12487 0.095 0.118 4.694 91.122 1839 9.72098E-09 
2.19064 313 12233 0.118 0.152 4.599 91.004 2266 1.24737E-08 
2.2204 235 11920 0.088 0.119 4.481 90.853 1701 9.75211E-09 
2.25056 259 11685 0.097 0.136 4.393 90.734 1875 1.1192E-08 
2.28113 236 11426 0.089 0.129 4.295 90.598 1709 1.06194E-08 
2.31211 238 11190 0.089 0.136 4.206 90.469 1723 1.11517E-08 
2.34352 226 10952 0.085 0.134 4.117 90.333 1636 1.10269E-08 
2.37535 215 10726 0.081 0.133 4.032 90.199 1557 1.09234E-08 
2.40762 212 10511 0.08 0.136 3.951 90.066 1535 1.1216E-08 
2.44032 220 10299 0.083 0.147 3.872 89.93 1593 1.21199E-08 
2.47347 203 10079 0.076 0.142 3.789 89.783 1470 1.16454E-08 
2.50706 211 9876 0.079 0.153 3.713 89.641 1528 1.26042E-08 
2.54112 185 9665 0.07 0.14 3.633 89.488 1339 1.15076E-08 
2.57563 184 9480 0.069 0.145 3.564 89.348 1332 1.19181E-08 
2.61062 188 9296 0.071 0.154 3.495 89.203 1361 1.26802E-08 
2.64608 164 9108 0.062 0.14 3.424 89.049 1187 1.15183E-08 
2.68202 181 8944 0.068 0.161 3.362 88.909 1310 1.32374E-08 
2.71845 180 8763 0.068 0.167 3.294 88.748 1303 1.3708E-08 
2.75538 177 8583 0.067 0.171 3.226 88.581 1281 1.40364E-08 
2.7928 167 8406 0.063 0.168 3.16 88.411 1209 1.37903E-08 
2.83074 173 8239 0.065 0.181 3.097 88.243 1253 1.48759E-08 
2.86919 164 8066 0.062 0.179 3.032 88.062 1187 1.46845E-08 
2.90816 158 7902 0.059 0.179 2.97 87.884 1144 1.47316E-08 
2.94766 136 7744 0.051 0.161 2.911 87.704 985 1.32041E-08 
2.9877 176 7608 0.066 0.216 2.86 87.544 1274 1.77935E-08 
3.02828 141 7432 0.053 0.18 2.794 87.328 1021 1.48438E-08 
3.06942 166 7291 0.062 0.221 2.741 87.147 1202 1.81976E-08 
3.11111 145 7125 0.055 0.201 2.678 86.926 1050 1.6552E-08 
3.15337 125 6980 0.047 0.181 2.624 86.725 905 1.48584E-08 
3.1962 140 6855 0.053 0.211 2.577 86.544 1014 1.73287E-08 
3.23961 152 6715 0.057 0.238 2.524 86.333 1100 1.95911E-08 
3.28362 147 6563 0.055 0.24 2.467 86.095 1064 1.97294E-08 
3.32822 140 6416 0.053 0.238 2.412 85.855 1014 1.9566E-08 
3.37343 131 6276 0.049 0.232 2.359 85.617 948 1.90644E-08 
3.41925 143 6145 0.054 0.263 2.31 85.386 1035 2.16703E-08 
3.46569 124 6002 0.047 0.238 2.256 85.122 898 1.95672E-08 
3.51277 128 5878 0.048 0.256 2.21 84.884 927 2.10328E-08 
3.56048 138 5750 0.052 0.287 2.162 84.629 999 2.36125E-08 
3.60885 128 5612 0.048 0.277 2.11 84.341 927 2.28062E-08 
3.65787 117 5484 0.044 0.264 2.062 84.064 847 2.17074E-08 
3.70755 114 5367 0.043 0.268 2.018 83.8 825 2.20243E-08 
3.75791 102 5253 0.038 0.249 1.975 83.533 738 2.052E-08 
3.80896 120 5151 0.045 0.306 1.936 83.283 869 2.51384E-08 
3.86069 128 5031 0.048 0.339 1.891 82.977 927 2.79217E-08 
3.91313 109 4903 0.041 0.301 1.843 82.638 789 2.47592E-08 
3.96629 105 4794 0.039 0.302 1.802 82.337 760 2.48359E-08 
4.02016 100 4689 0.038 0.299 1.763 82.035 724 2.46302E-08 
4.07477 103 4589 0.039 0.321 1.725 81.736 746 2.6417E-08 
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4.13012 110 4486 0.041 0.357 1.686 81.414 796 2.93777E-08 
4.18622 113 4376 0.042 0.382 1.645 81.057 818 3.14255E-08 
4.24308 83 4263 0.031 0.292 1.603 80.675 601 2.40358E-08 
4.30071 102 4180 0.038 0.374 1.571 80.383 738 3.0758E-08 
4.35913 105 4078 0.039 0.401 1.533 80.009 760 3.29705E-08 
4.41834 101 3973 0.038 0.402 1.494 79.608 731 3.30245E-08 
4.47835 84 3872 0.032 0.348 1.456 79.207 608 2.86003E-08 
4.53918 90 3788 0.034 0.388 1.424 78.859 652 3.19089E-08 
4.60084 100 3698 0.038 0.449 1.39 78.471 724 3.69189E-08 
4.66333 97 3598 0.036 0.453 1.353 78.022 702 3.72904E-08 
4.72668 89 3501 0.033 0.433 1.316 77.569 644 3.56284E-08 
4.79088 100 3412 0.038 0.507 1.283 77.136 724 4.16853E-08 
4.85595 92 3312 0.035 0.486 1.245 76.629 666 3.99344E-08 
4.92191 87 3220 0.033 0.478 1.21 76.143 630 3.9324E-08 
4.98877 113 3133 0.042 0.647 1.178 75.665 818 5.31858E-08 
5.05653 84 3020 0.032 0.501 1.135 75.019 608 4.11694E-08 
5.12522 104 2936 0.039 0.645 1.104 74.518 753 5.30772E-08 
5.19483 99 2832 0.037 0.64 1.065 73.873 717 5.26122E-08 
5.26539 88 2733 0.033 0.592 1.027 73.233 637 4.8698E-08 
5.33691 89 2645 0.033 0.624 0.994 72.641 644 5.12858E-08 
5.40941 97 2556 0.036 0.708 0.961 72.018 702 5.82048E-08 
5.48288 99 2459 0.037 0.752 0.924 71.31 717 6.18584E-08 
5.55736 76 2360 0.029 0.601 0.887 70.558 550 4.94489E-08 
5.63284 83 2284 0.031 0.684 0.859 69.957 601 5.62338E-08 
5.70936 69 2201 0.026 0.592 0.827 69.273 500 4.86798E-08 
5.78691 76 2132 0.029 0.679 0.801 68.681 550 5.5833E-08 
5.86551 69 2056 0.026 0.642 0.773 68.002 500 5.27842E-08 
5.94518 86 1987 0.032 0.833 0.747 67.361 623 6.85063E-08 
6.02594 71 1901 0.027 0.716 0.715 66.528 514 5.88939E-08 
6.10779 59 1830 0.022 0.62 0.688 65.812 427 5.09614E-08 
6.19075 50 1771 0.019 0.547 0.666 65.192 362 4.49715E-08 
6.27484 70 1721 0.026 0.797 0.647 64.645 507 6.55606E-08 
6.36007 61 1651 0.023 0.723 0.621 63.848 442 5.94912E-08 
6.44646 46 1590 0.017 0.568 0.598 63.125 333 4.67153E-08 
6.53403 46 1544 0.017 0.591 0.58 62.557 333 4.8645E-08 
6.62278 53 1498 0.02 0.71 0.563 61.966 384 5.83625E-08 
6.71274 45 1445 0.017 0.627 0.543 61.256 326 5.15999E-08 
6.80392 55 1400 0.021 0.798 0.526 60.629 398 6.56716E-08 
6.89634 51 1345 0.019 0.771 0.506 59.83 369 6.34108E-08 
6.99001 45 1294 0.017 0.708 0.486 59.059 326 5.82617E-08 
7.08496 46 1249 0.017 0.754 0.47 58.351 333 6.20165E-08 
7.18119 48 1203 0.018 0.819 0.452 57.597 348 6.73857E-08 
7.27873 30 1155 0.011 0.533 0.434 56.778 217 4.38556E-08 
7.3776 38 1125 0.014 0.703 0.423 56.245 275 5.7845E-08 
7.47781 48 1087 0.018 0.925 0.409 55.541 348 7.60855E-08 
7.57939 36 1039 0.014 0.722 0.391 54.616 261 5.94213E-08 
7.68234 39 1003 0.015 0.815 0.377 53.894 282 6.7032E-08 
7.78669 36 964 0.014 0.783 0.362 53.079 261 6.44315E-08 
7.89246 37 928 0.014 0.838 0.349 52.296 268 6.89566E-08 
7.99966 27 891 0.01 0.637 0.335 51.457 195 5.23981E-08 
8.10832 38 864 0.014 0.934 0.325 50.82 275 7.67915E-08 
8.21846 38 826 0.014 0.972 0.311 49.887 275 7.99636E-08 
8.33009 35 788 0.013 0.932 0.296 48.914 253 7.66928E-08 
8.44324 32 753 0.012 0.888 0.283 47.982 232 7.30154E-08 
8.55792 39 721 0.015 1.127 0.271 47.094 282 9.2663E-08 
8.67417 22 682 0.008 0.662 0.256 45.968 159 5.44307E-08 
8.79199 31 660 0.012 0.971 0.248 45.306 224 7.98657E-08 
8.91141 20 629 0.008 0.652 0.236 44.335 145 5.36545E-08 
9.03246 24 609 0.009 0.815 0.229 43.683 174 6.7045E-08 
9.15515 25 585 0.009 0.884 0.22 42.868 181 7.27233E-08 
9.2795 23 560 0.009 0.847 0.211 41.983 167 6.96689E-08 
9.40555 25 537 0.009 0.959 0.202 41.136 181 7.88551E-08 
9.5333 25 512 0.009 0.998 0.192 40.178 181 8.21121E-08 
9.6628 24 487 0.009 0.998 0.183 39.179 174 8.20838E-08 
9.79405 20 463 0.008 0.866 0.174 38.181 145 7.12286E-08 
9.92708 30 443 0.011 1.353 0.167 37.316 217 1.11256E-07 
10.06192 21 413 0.008 0.986 0.155 35.963 152 8.10959E-08 
10.19859 18 392 0.007 0.88 0.147 34.977 130 7.23819E-08 
10.33712 23 374 0.009 1.171 0.141 34.097 167 9.63083E-08 
10.47753 20 351 0.008 1.06 0.132 32.926 145 8.72055E-08 
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10.61985 18 331 0.007 0.994 0.124 31.866 130 8.17269E-08 
10.7641 14 313 0.005 0.805 0.118 30.872 101 6.61909E-08 
10.91031 15 299 0.006 0.898 0.112 30.067 109 7.38482E-08 
11.05851 18 284 0.007 1.122 0.107 29.17 130 9.22783E-08 
11.20872 13 266 0.005 0.844 0.1 28.048 94 6.93983E-08 
11.36097 14 253 0.005 0.946 0.095 27.204 101 7.78236E-08 
11.51528 14 239 0.005 0.985 0.09 26.258 101 8.1038E-08 
11.6717 12 225 0.005 0.879 0.085 25.273 87 7.23304E-08 
11.83024 15 213 0.006 1.145 0.08 24.393 109 9.41476E-08 
11.99093 15 198 0.006 1.192 0.074 23.249 109 9.80363E-08 
12.1538 15 183 0.006 1.241 0.069 22.057 109 1.02086E-07 
12.31889 12 168 0.005 1.034 0.063 20.816 87 8.50419E-08 
12.48622 21 156 0.008 1.884 0.059 19.782 152 1.54971E-07 
12.65582 21 135 0.008 1.962 0.051 17.898 152 1.61372E-07 
12.82773 4 114 0.002 0.389 0.043 15.936 29 3.20071E-08 
13.00197 9 110 0.003 0.912 0.041 15.547 65 7.49907E-08 
13.17857 14 101 0.005 1.477 0.038 14.635 101 1.2147E-07 
13.35758 11 87 0.004 1.208 0.033 13.158 80 9.93833E-08 
13.53902 13 76 0.005 1.487 0.029 11.95 94 1.22304E-07 
13.72292 5 63 0.002 0.596 0.024 10.463 36 4.89832E-08 
13.90932 3 58 0.001 0.372 0.022 9.867 22 3.06039E-08 
14.09825 9 55 0.003 1.162 0.021 9.495 65 9.56038E-08 
14.28975 7 46 0.003 0.941 0.017 8.333 51 7.743E-08 
14.48385 4 39 0.002 0.56 0.015 7.392 29 4.60733E-08 
14.68059 4 35 0.002 0.583 0.013 6.831 29 4.79764E-08 
14.87999 4 31 0.002 0.607 0.012 6.248 29 4.9958E-08 
15.08211 0 27 0 0 0.01 5.641 0 0 
15.28697 2 27 0.001 0.329 0.01 5.641 14 2.70852E-08 
15.49462 3 25 0.001 0.514 0.009 5.311 22 4.23059E-08 
15.70508 4 22 0.002 0.714 0.008 4.797 29 5.87378E-08 
15.91841 3 18 0.001 0.558 0.007 4.083 22 4.5873E-08 
16.13463 4 15 0.002 0.774 0.006 3.525 29 6.36904E-08 
16.35379 1 11 0 0.202 0.004 2.751 7 1.65803E-08 
16.57593 0 10 0 0 0.004 2.549 0 0 
16.80108 2 10 0.001 0.437 0.004 2.549 14 3.59566E-08 
17.02929 2 8 0.001 0.455 0.003 2.112 14 3.74418E-08 
17.2606 3 6 0.001 0.711 0.002 1.657 22 5.84825E-08 
17.49505 0 3 0 0 0.001 0.946 0 0 
17.73269 0 3 0 0 0.001 0.946 0 0 
17.97356 0 3 0 0 0.001 0.946 0 0 
18.21769 0 3 0 0 0.001 0.946 0 0 
18.46515 1 3 0 0.29 0.001 0.946 7 2.38669E-08 
18.71596 0 2 0 0 0.001 0.656 0 0 
18.97018 1 2 0 0.315 0.001 0.656 7 2.58792E-08 
19.22786 0 1 0 0 0 0.341 0 0 
19.48903 1 1 0 0.341 0 0.341 7 2.80613E-08 
      Total Interior Volume 8.22522E-06 
 
